A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
i 
  
 
 
 
 
 
A PI[INVESTIGATOR_676815] O’NEIL LONG 
ACTING NALTREXONE IMPLANT  
  
Protocol Identifying Number: GM0017  
Principal Investigator: [INVESTIGATOR_124]. Adam Bisaga  
Sponsor: Go Medical Industries Pty Ltd  
Funded by: [CONTACT_133312]  1UG3DA047720 -01 
Version Number: GM0017 v  0.13 
11 June 2020 
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
ii 
 I. TABLE OF CONTENTS  
I. TABLE OF CONTENTS  ................................ ................................ ................................ .............  ii 
II. INDEX OF TABLES AND FIGURES  ................................ ................................ ........................  vi 
III. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................ .................... vii 
IV. STATEMENT OF COMPLIANCE  ................................ ................................ .............................  ix 
V. PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  x 
VI. SCHEMATIC OF STUDY DESIGN  ................................ ................................ .......................... XII 
1 KEY ROLES  ................................ ................................ ................................ .............................  13 
1.1 SPONSOR  ................................ ................................ ................................ ...............................  13 
1.2 PRINCIPAL INVESTIGATOR  ................................ ................................ ................................ .. 13 
1.3 INSTITUTE  ................................ ................................ ................................ ..............................  13 
1.3.1  SATELLITE LOCATION 1  ................................ ................................ ..............................  13 
1.3.2  SATELLITE LOCATION 2  ................................ ................................ ..............................  13 
1.4 CLINICAL LABORATORY  ................................ ................................ ................................ ....... 13 
1.5 CENTRAL CLINICAL LABORATORY  ................................ ................................ .....................  13 
1.6 RESPONSIBLE CLINICIAN  ................................ ................................ ................................ ..... 13 
1.7 IMPLANTATION PROCEDURE SURGEON  ................................ ................................ ...........  13 
1.8 SPONSOR REPRESENTATIVE  ................................ ................................ .............................  14 
1.9 INSTITUTE REPRESENTATIVE  ................................ ................................ .............................  14 
1.9.1  SATELLITE LOCATION 1 REPRESENTATIVE  ................................ ............................  14 
1.9.2  SATELLITE LOCATION 2 REPRESENTATIVE  ................................ ............................  14 
1.10  CLINICAL TRIAL CO -ORDINATOR  ................................ ................................ ........................  14 
1.11  STATISTICIAN  ................................ ................................ ................................ .........................  14 
1.12  CLINICAL RE SEARCH ASSOCIATE  ................................ ................................ ......................  14 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC  ................................ . [ADDRESS_915580]: O’Neil Long Acting Naltrexone Implant (OLANI) – In Vitro 
Information  ................................ ................................ ................................ .....................  16 
2.1.5  OLANI: Clinical Trials  ................................ ................................ ................................ ..... 18 
2.1.6  Clinical Use Summary  ................................ ................................ ................................ .... 19 
2.2 STUDY RATIONALE  ................................ ................................ ................................ ...............  24 
2.3 POTENTIAL RISKS AND BENEFITS  ................................ ................................ ......................  24 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ... 24 
2.3.2  Known Potential Benefits  ................................ ................................ ...............................  25 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ...............................  26 
3.1 PRIM ARY OBJECTIVES  ................................ ................................ ................................ .........  26 
3.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ... 26 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
iii 
 4 STUDY DESIGN AND ENDPOINTS  ................................ ................................ .......................  27 
4.1 DESCRIPTION OF THE STUDY DESIGN  ................................ ................................ ..............  27 
4.2 STUDY ENDPOINTS  ................................ ................................ ................................ ...............  27 
4.2.1  Primary Endpoint ................................ ................................ ................................ ............  27 
4.2.2  Secondary Endpoints  ................................ ................................ ................................ ..... 27 
4.2.3  Primary Efficacy Endpoint:  ................................ ................................ .............................  27 
4.2.4  Secondary Efficacy Endpoints:  ................................ ................................ ......................  27 
4.2.5  Exploratory Efficacy Endpoints:  ................................ ................................ .....................  27 
5 STUDY ENROLMENT AND WITHDRAWAL  ................................ ................................ ...........  28 
5.1 PARTICIPANT INCLUSION CRITERIA  ................................ ................................ ...................  28 
5.2 PARTICIPANT EXCLUSION CRITERIA  ................................ ................................ .................  28 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  ................................ ........................  29 
5.3.1  Target Sample Size:  ................................ ................................ ................................ ...... 29 
5.3.2  Recruitment  ................................ ................................ ................................ ....................  29 
5.3.3  Retention  ................................ ................................ ................................ ........................  30 
5.4 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................ ...............................  30 
5.4.1  Reasons for Withdrawal or Termination  ................................ ................................ ........  30 
5.4.2  Handling of Participant Withdrawals or Termination  ................................ ......................  30 
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  ................................ ..............  31 
6 STUDY AGENT  ................................ ................................ ................................ .......................  32 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  ................................ .............................  [ADDRESS_915581] Storage and Stability  ................................ ................................ ........................  34 
6.1.4  Preparation  ................................ ................................ ................................ .....................  34 
6.1.5  Dosing and Administration  ................................ ................................ .............................  34 
6.1.6 Route of Administration  ................................ ................................ ................................ .. 34 
6.1.7  Starting Dose and Dose Escalation Schedule  ................................ ...............................  35 
6.1.8  Dose Adjustments/Modifications/Delays  ................................ ................................ ........  35 
6.1.9  Duration of Therapy  ................................ ................................ ................................ ....... 35 
6.1.10  Tracking of Dose  ................................ ................................ ................................ ............  35 
6.1.11  Device Specific Considerations  ................................ ................................ .....................  35 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ................................ ............................  35 
7 STUDY PROCEDURES AND SCHEDULE  ................................ ................................ .............  36 
7.1 STUDY PROCEDURES/EVALUATIONS  ................................ ................................ ................  36 
7.1.1  Study Specific Procedures  ................................ ................................ .............................  36 
7.2 LABORATORY PROCEDURES/EVALUATIONS  ................................ ................................ ... 42 
7.2.1  Clinical Laboratory Evaluations  ................................ ................................ ......................  42 
7.2.2  Other Assays or Procedures  ................................ ................................ ..........................  43 
7.2.3  Total amount of Blood to be collected  ................................ ................................ ...........  43 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
iv 
 7.2.4  Specimen Preparation, Handling and Storage  ................................ ..............................  44 
7.2.5  Specimen Shipment  ................................ ................................ ................................ ....... 44 
7.3 STUDY SCHEDULE  ................................ ................................ ................................ ................  44 
7.3.1  Screening Visit 1  ................................ ................................ ................................ ............  44 
7.3.2  Screening Visit 2  ................................ ................................ ................................ ............  45 
7.3.3  Recruitment Visit  ................................ ................................ ................................ ............  45 
7.3.4  Day -1 to Day 2 (‘Admission’ Days)  ................................ ................................ ...............  45 
7.3.5  Follow -Up Day 4 to 540  ................................ ................................ ................................ . 46 
7.3.6  Final Study Visit  ................................ ................................ ................................ .............  47 
7.3.7  Early Termination Visit  ................................ ................................ ................................ ... 47 
7.3.8  Unscheduled Visit  ................................ ................................ ................................ ..........  47 
7.3.9  PK F ollow -up Visit  ................................ ................................ ................................ ..........  47 
7.3.10  AE Follow -up Visit  ................................ ................................ ................................ ..........  47 
7.3.11  Assessment Time Point Tables  ................................ ................................ .....................  48 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS AND PROCEDURES  ..............................  51 
7.5 PROHIBITED MEDICATIONS, TREATMENTS AND PROCEDURES  ................................ ... 51 
7.6 PROPHYLACTIC MEDICATIONS, TREATMENTS AND PROCEDURES  .............................  51 
7.6.1  Prophylactic Medications  ................................ ................................ ...............................  51 
7.6.2 Management of Infection/ Inflammatory Responses to the Wound/Implant Site  ...........  51 
7.7 RESCUE MEDICATIONS, TREATMENTS AND PROCEDURES  ................................ ..........  53 
7.8 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ................................ ... 53 
7.9 REIMBURSEMENT COSTS  ................................ ................................ ................................ .... 54 
8 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ... 55 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ................................ ................................ ...... 55 
8.1.1  Definition of Adverse Events (AE) ................................ ................................ ..................  55 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ ................................ .. 55 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ................................ ................................ ........  56 
8.2.1  Severity of Event  ................................ ................................ ................................ ............  56 
8.2.2  Relationship to Study Medication and Surgical Procedure  ................................ ............  56 
8.2.3  Expectedness ................................ ................................ ................................ .................  57 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ..........  58 
8.4 REPORTING PROCEDURES  ................................ ................................ ................................ . 58 
8.4.1  Adverse Event Reporting  ................................ ................................ ...............................  58 
8.4.2  Serious Adverse Event Reporting  ................................ ................................ ..................  58 
8.4.3  Reporting of Pregnancy  ................................ ................................ ................................ . 59 
8.5 STUDY HALTING RULES  ................................ ................................ ................................ ....... 59 
8.5.1  Study Termination  ................................ ................................ ................................ ..........  59 
8.5.2  On-Site Audits  ................................ ................................ ................................ ................  60 
8.6 DATA AND SAFETY MONITORING PLAN ADMINISTRATION  ................................ .............  60 
8.6.1  Responsibility for data and safety monitoring (DSM)  ................................ .....................  60 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
v 
 8.6.2  Frequency of DSM  ................................ ................................ ................................ .........  60 
8.6.3  DSMB Plan  ................................ ................................ ................................ .....................  60 
9 CLINICAL MONITORING  ................................ ................................ ................................ ........  61 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ .........................  62 
10.1  STATISTICAL AND ANALYTICAL PLANS ................................ ................................ ..............  62 
10.2  STATISTICAL HYPOTHESES  ................................ ................................ ................................  62 
10.3  ANALYSIS DATASETS  ................................ ................................ ................................ ...........  62 
10.4  DESCRIPTION OF STATISTICAL METHODS  ................................ ................................ ....... 62 
10.4.1  General Approach  ................................ ................................ ................................ ..........  62 
10.4.2  Analysis of the Primary Endpoint  ................................ ................................ ...................  62 
10.4.3  Analysis of the Secondary and Exploratory Endpoint(s)  ................................ ...............  62 
10.4.4  Safety Analyses  ................................ ................................ ................................ .............  62 
10.4.5  Adherence and Retention Analyses ................................ ................................ ...............  63 
10.4.6  Baseline Descriptive Statistics  ................................ ................................ .......................  63 
10.4.7  Planned Interim Analyses  ................................ ................................ ..............................  63 
10.4.8  Additional Sub -Group Analyses  ................................ ................................ .....................  63 
10.4.9  Multiple Comparison/ Multiplicity  ................................ ................................ ....................  63 
10.4.10  Tabulation of Individual Response Data  ................................ ................................ ........  63 
10.4.11  Exploratory Analyses  ................................ ................................ ................................ ..... 63 
10.5  SAMPLE SIZE  ................................ ................................ ................................ .........................  64 
10.6  MEASURES TO MINIMIZE BIAS  ................................ ................................ ............................  64 
10.6.1  Enrolment/ Randomization/ Masking Procedures  ................................ ..........................  64 
10.6.2  Evaluation of Success of Blinding  ................................ ................................ ..................  64 
10.6.3  Breaking the Study Blind/Participant Code  ................................ ................................ .... 64 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .......................  64 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ................................ ..............................  64 
13 ETHICS/PROTECTION OF HUMAN PARTICIPANTS  ................................ ...........................  [ADDRESS_915582]  ................................ ................................ .........................  65 
13.3  INFORMED CONSENT PROCESS  ................................ ................................ ........................  65 
13.3.1 Consent/Assent and Other Informational Documents Provided to Participants  ............  [ADDRESS_915583] KEEPI[INVESTIGATOR_1645]  ................................ ................................ .........  67 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES ................................ ..........  67 
14.2  STUDY RECORDS RETENTION  ................................ ................................ ............................  67 
14.3  PROTOCOL DEVIATIONS  ................................ ................................ ................................ ...... 67 
14.4  PUBLICATION AND DATA SHARING POLICY  ................................ ................................ ...... 68 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
vi 
 [ADDRESS_915584] POLICY  ................................ ................................ ........................  68 
17 REVISION HISTORY  ................................ ................................ ................................ ...............  69 
18 SUMMARY OF CHANGES FROM PREVIOUS VERSION  ................................ .....................  69 
18.1  Version 0.6  ................................ ................................ ................................ ...............................  69 
18.2  Version 0.7  ................................ ................................ ................................ ...............................  72 
18.3  Version 0.8  ................................ ................................ ................................ ...............................  72 
18.4  Version 0.9  ................................ ................................ ................................ ...............................  73 
18.5  Version 0.10  ................................ ................................ ................................ .............................  74 
18.6  Version 0.11  ................................ ................................ ................................ .............................  75 
18.7  Version 0.12  ................................ ................................ ................................ .............................  76 
19 LITERATURE REFERENCES  ................................ ................................ ................................ . 77 
 
II. INDEX OF TABLES AND FIGURES  
Table 2 -1: List of Clinical Trials Performed During the Development of OLANI  .................  18 
Table 2 -2: Total number of second generation OLANI used sorted by [CONTACT_3148]  ..................  19 
Table 2 -3: Opi[INVESTIGATOR_676816] 2016 and January 
2018 for GM 2nd Generation OLANI’s  ................................ ................................ . 20 
Table 2 -4: Opi[INVESTIGATOR_676817]10 description.  ................................ ....................  21 
Table 2 -5: Opi[INVESTIGATOR_676818]’s by [CONTACT_48334]10 description.  ................................ ....................  22 
Table 2 -6: Treatment of AEs & SAE’s reported as ‘Inflammatory reaction due to implants’  23 
Table 7 -1: Assessment Time Points  ................................ ................................ .........................  48 
 
Figure 2.1: Comparison of release rate of spray coated (second generation) vs dip coated (first 
generation), release specification limits highlighted  ................................ .............  17 
Figure 2.2: Causality Groups  ................................ ................................ ................................ ... 20 
Figure 6.1: Applicator with OLANI pellets  ................................ ................................ .............  32 
Figure 6.2: Applicator with tablets exposed for delivery  ................................ ........................  33 
Figure 6.3: First layer packaging  ................................ ................................ .............................  33 
Figure 6.4: Second layer packaging  ................................ ................................ .........................  34 
Figure 7.1: Usual OLANI placement  ................................ ................................ .......................  37 
Figure 7.2: Target insertion of local anesthetic  ................................ ................................ ....... 38 
Figure 7.3: Correct holding of syringe applicator  ................................ ................................ .... 39 
Figure 7.4: Syringe applicator insertion ................................ ................................ ...................  40 
Figure 7.5: Insertion of OLANI using Syringe plunger  ................................ ...........................  41 
Figure 7.6: Correct positioning of OLANI  ................................ ................................ ..............  41 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
vii 
 III. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Term or Abbreviation  Description  
6βN 6-β-naltrexol  
ADR  Adverse Drug Reaction  
AE Adverse Event  
AMPRF  Australian Medical Procedures Research Foundation  
AUC  Area Under the Curve  
BDI Beck Depression Inventory -II 
CMP  Clinical Monitoring Plan  
COWS  Clinical Opi[INVESTIGATOR_676819], Urea, Creatinine  
FBC Full Blood Count  
FCP Full Chemistry Panel  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
HREC  Human Research Ethics Committee  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
IP Investigational Product  
IRB Institutional Review Board  
LFT Liver Function Tests  
MEC  Minimum Effective Concentration  
MSDS  Material Safety Data Sheet  
NCT  Naloxone Challenge Test  
NTX  Naltrexone  
NYSPI  [INVESTIGATOR_676820]  O’Neil Long Acting Naltrexone Implant  
PHQ  Patient Health Questionaire  
PI [INVESTIGATOR_676821]  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
viii 
 Term or Abbreviation  Description  
UA Urinalysis  
UDS  Urine Drug Screen  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SLV  Since Last Visit  
SMC  Safety Monitoring Committee  
SOP Standard Operating Procedure  
SURC  Substance Use Research Center  
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
x 
 V. PROTOCOL SUMMARY  
Title:  A PI[INVESTIGATOR_676815] O’NEIL 
LONG ACTING NALTREXONE IMPLANT  
Overview:  A Phase I/II, Single Arm, Open Label study measuring the 
Pharmacokinetics of the O’Neil Long Acting Naltrexone Implant 
(OLANI).  
This study will examine the pharmacokinetic profile  of OLANI over 
[ADDRESS_915585] (NCT) to confirm opi[INVESTIGATOR_676822]. All p articipants will be treated 
with a double  administration of a 1.8g ( ) OLANI  in an open label 
manner . No randomization  will occur.  
Objectives:  Primary :   
To characterize the pharmacokinetic profile (C max, Tmax, AUC , 
T>MEC, where MEC  = 1.3 3 ng/m L NTX , Time to C0 for naltrexone) 
of the OLANI (2  units).  
Primary outcomes used to determine these propertie s will be based on 
results from p lasma concentration of naltrexone and 6 -β-naltrexol as 
ascertained from blood samples taken at the following time points :  
- 0, 3, 6, 12, 24, 48 hours  
- 4, 8, 14, 21, 28, 35, 42, 49, 56, 90, 120, 150 , 180, 210, 240, 
270, 300, 330, 360, 390, 420, 450, 480, 510 & 540 days.  
Note: 1.33 ng/mL is a target MEC for this protocol. The MEC will be 
further developed over time.  
Secondary :  
• To characterize the safety profile (i.e. adverse events, laboratory 
results, wo und site and inflammatory response rates) of the 
OLANI.   
Endpoint:  Primary:  
The collection of at least 75% pharmacokinetic blood time points 
including 2 consecutive monthly naltrexone blood levels recorded at 
<0.1 ng/mL  in 10 participants.  
Primary Efficacy Endpoint:  
Proportion of participants who tolerate OLANI and maintain blood 
level of naltrexone of at least 1.3 3 ng/m L at all collected time points to 
≥180 day time point .  
Population:  20 health y participants ( 10 male, 10 female), aged between 18 and 55 
years old, without a DSM 5 - Substance Related Disorders 
classification . 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
xi 
 Phase:  I/II 
Number of 
Sites:  One site: Substance Use Research Centre (SUR C), [LOCATION_001] State 
Psychiatric Institute, [ADDRESS_915586], [LOCATION_001], NY [ZIP_CODE], 
[LOCATION_003]  (initial assessment , follow up to 48 hours , Final Visit or Early 
Termination Visit, and additional follow up visits as appropriate ) 
Satellite Location  1: Columbia University Medical Center  (CUMC) , 
[ADDRESS_915587]., Ne w York, NY [ZIP_CODE], [LOCATION_003]  (IP 
administration)  
Satellite Location  2: Clinilabs, [ADDRESS_915588], [LOCATION_001], [ZIP_CODE] 
(post 48 hour follow -up) 
Investigation
al Product:  The investigational product is the O’Neil Long Acting Na ltrexone 
Implant (1.8g, ) x [ADDRESS_915589] is a 
biodegradable implant which is administered subcutaneously using a 
minor surgical procedure under local anesthetic . 
Study 
Duration:  Estimated 22 months  
Participant 
Duration:  540 days 
  

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915590]., [LOCATION_001], NY [ZIP_CODE]  
 
1.3 INSTITUTE  
Substance Use Research Center (SURC), [LOCATION_001] State Psychiatric Institute, [ADDRESS_915591]., Unit 120, [LOCATION_001], NY [ZIP_CODE]  (Initial assessment , follow up to 48 hours , 
Final Visit or Early Termination Visit, and additional follow up visits as appropriate ) 
1.3.1 SATELLITE LOCATION  1 
Columbia  University Medical Center (CUMC), [ADDRESS_915592]., [LOCATION_001], NY 
[ZIP_CODE] (IP administration)  
1.3.[ADDRESS_915593], [LOCATION_001], [ZIP_CODE] (post 48 hour follow -up) 
 
1.4 CLINICAL LABORATORY  
PK analysis of naltrexone and 6 - -naltrexol will be performed by a qualified bioanalytic 
laboratory. No other clinical labs will be performed.  
 
1.5 CENTRAL CLINICAL LABORATORY  
(LFT, FBC, EUC, URINE DRUG SCREEN AND ROUTINE PATHOLOGY)  
Laboratory Corporation of America  
 
1.[ADDRESS_915594] Certified in Plastic Surgery  
Chief of Microvascular Services, Department of Surgery  
Columbia University Medical Center  
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 14 of 78 1.8 SPONSOR REPRESENTATIVE  
[CONTACT_676907] -Tark Chan BSc (IT) BEng (Mech) Hons  
Operations Manager, Pharmaceutical Division  
Go Medical Industries Pty Ltd  
 
1.[ADDRESS_915595]., Unit 120, [LOCATION_001], NY [ZIP_CODE]  
1.9.1 SATELLITE LOCATION 1  REPRESENTATIVE  
Christine Rohde, MD, MPH, FACS  
Columbia University Medical Center (CUMC), [ADDRESS_915596], [LOCATION_001], [ZIP_CODE]  
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 15 of 78 2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC  
2.1 BACKGROUND INFORMATION  
Naltrexone (NTX) is a synthetic derivative of thebaine, a minor constituent of opi[INVESTIGATOR_1890]. It is a 
nonspecific pure opi[INVESTIGATOR_9727] . NTX binds competitively to all classes of opi[INVESTIGATOR_676823] µ>κ>δ, with a high affinity for the µ -opi[INVESTIGATOR_162223]. It blocks the effects of opi[INVESTIGATOR_676824]. NTX is 
approved by [CONTACT_676874][INVESTIGATOR_2561]/opi[INVESTIGATOR_2427] (OUD)  and 
is also approved for the treatment of alcohol use disorder.  NTX is curren tly registered in [LOCATION_003] 
as a once daily oral formulation containing 50 mg of NTX  and as a once -monthly injectable 
formulation containing 380 mg of NTX.  
2.1.1 Metabolism  of Naltrexone  
NTX is well absorbed orally (96%), but it undergoes a significant first pass me tabolism 
resulting in only 5 to 40% oral bioavailability. Naltrexone is extensively metabolized in 
humans1. Production of the primary metabolite, 6β -naltrexol  (6-BN), is mediated by 
[CONTACT_565075], a cytosolic family of enzymes.  Two other minor metabolites are 
2-hydroxy -3-methoxy -6β-naltrexol and [ADDRESS_915597] been reported as ranging from 2 to 10  hours for naltrexone3–[ADDRESS_915598] as they would shortly after completing 
detoxification. This could result in potentially life -threatening opi[INVESTIGATOR_9845] (respi[INVESTIGATOR_676825], circulatory collapse, etc.) if the patient uses previously tolerated doses 
of opi[INVESTIGATOR_2438]9. 
Better NTX compliance has been obse rved when a responsible adult is available to supervise 
daily NTX dosing10. It has been reported that the method of daily o ral NTX treatment is not 
an affective long term treatment in most patients11,12. Clinical data has indicated that poor 
medication c ompliance occurs with daily oral NTX maintenance treatment for opi[INVESTIGATOR_2560]8,10,13. It has been proposed that the development of a sustained release NTX 
preparation would combat these issues and lead to improved outcomes for opi[INVESTIGATOR_45157].  
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 16 of 78 2.1.3 Sustained Release Preparations  
Wise (1984) developed a NTX (70%) -poly(D,L -lactide -co-glycolide) copolymer (30%) 
implant14, which was the first biodegradable drug delivery system appr oved by [CONTACT_4469] (FDA) for clinical testing, but was limited by “burst release” in human 
trials. Previous findings also suggested that polymeric NTX sus tained release systems are 
biocompatible formulations15,16. Additionally, several dosage forms have also bee n proposed. 
For example, a NTX -poly(lactic acid) composite17, which had an effective blocking action to 
morphine in rats for 24 days; NTX -copolymer (90% L -lactic acid and 10% glycolic acid) 
beads18,which would provide constant NTX levels for one month, and a NTX p amoate linear 
poly(ortho esters) disk19, which released NTX pamoate for [ADDRESS_915599] s of a NTX PLGA microsphere suspension 
delivered intram uscularly via an injection. Some studies revealed that a 380 mg injection can 
produce a blood NTX level of 1.2 ng/mL for approximately four weeks22. However, Vivitrol 
has been found to give dose-dependent effects with some a dverse events23. 
2.1.[ADDRESS_915600] : O’Neil Long Acting Naltrexone Implant (OLANI) – In 
Vitro Information  
Basic composition of the OLANI  formulations is a proprietary combination o f  
 
. 
The manufacturing process has been developed from its original laboratory scale and refined 
to more commercial Good Manufac turing Practice (GMP) techniques via a process of 
upscaling. Therefore , the investigational product has evolved into two generations of product. 
The first generation of investigational product was manufactured under smaller scale R&D 
production. Initially the manufacturing tolerances for early investigational product were 
reflective of manufacturing capability and were set as  
. 
During product development and upscaling, the manufacturing process was improved to 
allow for more commercially sized manufacturing equipment to be i mplemented and a 
reduction in residual solvent levels in the final product. The variation itself consists of  
 
 
 
 
.  
The second generatio n of product using the  
 
 
 
 
 
 
 
. 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915601] is low.  
The biodegradable polylactic based polymer is used in a variety of products  e.g. 
 
   
 , 
with the authors estimating an incidence of foreign body reaction of 4.9%, from accumulated 
data from [ADDRESS_915602] and second generation 
products.   
Figure 2.1: Comparison of release rate of spray coated (second generation) vs dip coated (first 
generation), release specification limits highlighted  
 
Dissolution data indicates appropriate sustained release characteristics maintained for over 
six months and satisfactory batch -to-batch consistency. The variation between manufacturing 
formulation for first and second generation implants is not considered to be significant as 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 24 of 78 ‘fluid drainage /site cleaned’  0.97% (5 in 515), ‘non-surgical removal’ 0.58% (3 in 515) or 
surgical removal 0.38% (2 in 515).  
The majority of inflammatory reports occur within the first [ADDRESS_915603] was r elated to withdrawal state - 
opi[INVESTIGATOR_2573] 6.21% (32 in 515) and other associated drug withdrawal symptoms (Insomnia, 
Anxiety, Depression and Nausea) 7.96% (41 in 515).  
Overall it can be concluded that the OLANI is safe and that the perception of efficacy 
amongst patients has outweighed any perceived inconvenience arising from the mild 
inflammatory reactions that have been observed. A method for treatment of inflammatory 
responses is effective with only a small amount of procedures requiring removal of an 
implant for an unresolved inflammatory response. It is also important to have good treatment 
plans in place to help patients post implantation to deal with the expected withdrawal 
symptoms and adjustment to a change in lifestyle from opi[INVESTIGATOR_9825] . 
 
2.[ADDRESS_915604] pi[INVESTIGATOR_676826] a DSM 5 - Substance Related 
Disorders classification . The use of healthy non-substanc e dependent volunteers for this 
protocol greatly reduces the risk of opi[INVESTIGATOR_676827]’s and opi[INVESTIGATOR_676828] -therapeutic naltrexone blood levels being recorded.  This pi[INVESTIGATOR_676829] a large bioequ ivalence study on the OLANI.  
 
2.3 POTENTIAL RISKS AND BENEFITS  
2.3.1 Known Potential Risks  
1. When the local anesthetic  used during OLANI insertion wears off, the site of 
implantation may be tender.  
2. The OLANI may cause irritation or inflammation at or near the site of administration 
as a result of an allergic response or other inflammatory process.  
3. There is a risk of infe ction with any surgical procedure of this type. The risk is 
minimized  by [CONTACT_676875].  
4. In the unlikely event the participant  requires narcotic pa inkillers for severe pain; most 
will have a greatly reduced effect whilst naltrexone is still being released from the 
OLANI  and higher doses of high potency opi[INVESTIGATOR_676830] . In instances 
where pain cannot be controlled by [CONTACT_11174] (such as r egional blocks or 
alternative drugs  see section 7.7) the OLANI may have to be removed surgically.   
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 25 of 78 5. Known side -effects from naltrexone include diffi culty sleepi[INVESTIGATOR_007], anxiety, nervousness, 
abdominal pain/cramps, nausea and/or vomiting, low energy, join and muscle pain, 
headache, loss of appetite, diarrhea , constipation, increased thirst, increased energy, 
depressive mood, irritability, dizziness, skin ra sh, delayed ejaculation, erection 
dysfunction , reduced sexual desire, and chills . 
6. Naltrexone has been associated with reversible hepatocellular injury indicated by 
[CONTACT_676876]. When used in the lower dose range in opi[INVESTIGATOR_676831], this risk is remote26,27. Naltrexone is th erefore contraindicated in participant s 
with acute hepatitis or liver failure, and such participant s are excluded from the study. 
Participant s with hepatic enzyme levels greater than three times the upper limit of 
normal are ex cluded. Implantable naltrexone achieves lower blood levels than oral 
naltrexone initially, and blood level  should remain lower throughout treatment period 
than levels associated with hepatitis. If naltrexone  induced hepatitis were to occur in 
the setting o f long -acting preparation, where the naltrexone would be only very 
slowly eliminated, this would prolong exposure to the offending agent. However, the 
experience with injectable and implantable naltrexone also suggests it is safe. In 
studies with injectabl e naltrexone several participant s experienced elevation in liver 
enzymes, which were determined to be related to hepatitis C. Several recent reports 
with injectable naltrexone showed that it poses significantly lower risk of 
hepatotoxicity than previously suspected, even among alcohol and opi[INVESTIGATOR_2480] -dependent 
persons including those with HCV and/or HIV infection28–31. In July of 2013, the 
Boxed Warning on the hepatotoxicity was removed from the Vivitrol Package Insert.”  
7. Naloxone injection may cause withdrawal symptoms such as nausea, vomiting, 
diarrhea, stomach pain, fever, sweating, body aches, weakness, running nose, 
goosebumps, shivering, increased heart rate, and anxiety.  
 
2.3.[ADDRESS_915605] through the registration process and onto the market.  
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 26 of 78 3 OBJECTIVES AND PURPOSE  
3.1 PRIMARY OBJECTIVES  
To characterize the pharmacokinetic profile (C max, Tmax, AUC , T>MEC, where 
MEC  = 1.33 ng/m L NTX , Time to C0 for naltrexone) of the OLANI (2 units).  
Primary outcomes used to determine these properties will be based on results from plasma 
concentration of naltrexone and 6 -β-naltrexol as ascertained from blood samples taken at the 
following time points:  
• 0, 3, 6, 12, 24, 48 hours  
• 4, 8, 14, 21, 28, 35, 42, 49, 56, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420, 
450, 480, 510 & 540 days . 
Note: 1.33 ng/mL is a target MEC for this protocol. The MEC will be further developed over 
time.  
3.2 SECONDARY OBJECTIVES  
• To characterize the safety profile (i.e. AEs, laboratory results, wound site and 
inflammatory response rates) of the OLANI.  
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 27 of 78 4 STUDY DESIGN AND ENDPOINTS  
4.1 DESCRIPTION OF THE STUDY DESIGN  
This pi[INVESTIGATOR_9962] a phase I/II, open label , single -arm pharmacokinetic trial of the OLANI  in 
healthy participants without a DSM 5 - Substance Related Disorders classification . PK data 
will be collected in all participants until 2 consecutive monthly naltrexone blood levels 
recorded at <0.1 ng/mL , it is anticipated that this will occur by [CONTACT_2006] 540.  Participants will be 
required to undergo a Naloxone Challenge Test (NCT) to confirm absence of physiological 
dependence on opi[INVESTIGATOR_676832] . Participant s will be 
recrui ted, treated and followed up at  the SURC  clinic at the NYSPI . 
All p articipants will be treated with a double  administration of a 1.8g ( ) OLANI.  
 
4.2 STUDY ENDPOINTS  
4.2.1 Primary Endpoint  
• The collection of at least 75% pharmacokinetic blood time points including 2 consecutive 
monthly naltrexone blood levels recorded at <0.1  ng/mL , in 10 participants.  
 
4.2.2 Secondary Endpoints  
• Detailed PK characteristics of the product.  
• The collection of safety information and AEs information over 540 days in participants 
treated with the OLANI.  
 
4.2.3 Primary Efficacy Endpoint:  
• Proportion of participants who tolerate OLANI and maintain blood level of naltrexone of 
at least 1.3 3 ng/m L at all collected time points to 180 day time point.  
 
4.2.4 Secondary Efficacy Endpoint s: 
• Mean Cmax, Tmax, AUC  for naltrexone blood level  
• Mean T>MEC  for naltrexone , where MEC = 1.3 3 ng/m L  
• Mean Cmax, Tmax, AUC for 6β-naltrexol  blood level  
• Frequency of AEs and SAEs  
 
4.2.5 Exploratory Efficacy Endpoints:  
• Use of drugs (opi[INVESTIGATOR_2438], cocaine, marijuana) and alcohol, as reported by [CONTACT_676877]  (UDS).  
 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915606] also be:  
1. Men or women between the ages of 18 and 55 years old  (inclusive)  
2. Without DSM 5 - Substance Related Disorders classification ; in sustained remission is 
not exclusionary  
3. Able and willing to comply with the requirements of the protocol  
4. Able and willing to provide written informed consent  
5. Willing to undergo a minor surgical procedure under local anesthetic  to allow for 
investigational drug administra tion in the subcutaneous tissue  
6. Have an i nitial weight between 45.3 and 81.6 kilograms (inclusive)  or have a BMI 
inclusive of 18.5 to 30.0  
 
5.2 PARTICIPANT EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in 
this study:   
1. Positive UDS at screening for illicit substances.  
2. Is currently on naltrexone medication.  
3. Has had a naltrexone implant in the past [ADDRESS_915607] (e.g. Vivitrol) in the past [ADDRESS_915608] the implant site area, or as determined b y the evaluating physician . 
10. Demonstrates any abnormal skin tissue in the proposed implantation area.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915609] at 
screening . Women need to agree to practice dual contraceptives.  
12. Particip ant is breastfeeding or planning to be.  
13. Has a current significant neurological (including cognitive and psychiatric disorders), 
hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological  or 
metabolic disease unless currently controlled and stable with protocol -allowed medication 
[ADDRESS_915610] administration.  
14. Any clinically important abnormal finding as determined by [CONTACT_9870], physical 
examination, ECG or clinical laboratory tests.  
15. Any additional condition(s) that in the investi gator’s opi[INVESTIGATOR_676833].  
16.  ALT  or AST  > [ADDRESS_915611] history  (in remission DSM 5 classification)  of anxiety or de pression is 
not exclusionary.    
19. Any elevated risk for suicide measured using the Columbia Suicide Severity Rating 
Scale , endorsing any of the items in the past month  (C-SSRS , Lifetime ) 
20. Is participating or intending to participate in any other clinical trial during the duration of 
this study.  
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
5.3.1 Target Sample Size:  
A total of 20 participants ( 10 females and 10 males) will be recruited. We expect that 10 of 
the 20 participants will complete the study  (50%) , which is providing at least 75% valid 
pharmacokinetic blood samples including 2 monthly naltrexone blood levels recorded at 
<0.1 ng/mL . 
 
5.3.[ADDRESS_915612] for a screening evaluation and mental status examination as part of routine 
admission procedures at SURC . Final informed consent for the study will be obtained after 
full psychiatric and medical worku p is complete. The research staff knows the protocol well 
and is able to explain study to the participant. Procedures for training staff physicians in each 
protocol and consent form include initial presentations by [CONTACT_079] (PI) at 
weekly  staff meetings, and weekly discussion of inclusion/exclusion criteria and study 
eligibility for each screening participant.  
The use of the Contract Research Organization  (CRO) Clinilabs, will also allow access to 
their participant database where the major ity of healthy volunteers are expected to be 
recruited.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915613] with participants to confirm each visit, and to reschedule in 
case of the missed visit.  
 
5.4 PARTICIPANT WITHDRAWAL OR T ERMINATION  
5.4.1 Reasons for Withdrawal or Termination  
• A participant may withdraw from the study at any time or for any reason without being 
obliged to divulge their reason for doing so to the investigators or clinic staff.  
• A participant may be withdrawn from t he study if there are unacceptable AEs, laboratory 
abnormality or any other medical condition or situation including distress due to effects 
of any study procedure or medication.  
• A participant may be withdrawn from the study if in the opi[INVESTIGATOR_676834] ’s interests are best served by [CONTACT_64492].  
• A participant may be withdrawn from the study if the participant meets an exclusion 
criterion (either newly developed or not previously recognized) that precludes fur ther 
study participation.  
• Participant will be withdrawn from the study if they fail the naloxone challenge test.  
 
5.4.2 Handling of Participant Withdrawals or Termination  
Participants, who do not receive the study medication (OLANI) , for any reason, are not 
considered treatment failures.  A participant  may be discontinued from the study at any time if 
the participant , investigator, or sponsor determines that it is not in the best interest of the 
participant  to continue participation. Reasons for discontinuation may include:  
• Adverse event  
• Withdrawal of participant  
• Lost to follow -up 
• Study terminated by [CONTACT_1697]  
• Pregnancy  
• Clinical worsening  
• Other  
• Screen Failure  
 
[IP_ADDRESS]  Participant  Monitoring and Removal from Study  
Medical staff  will assess  and communicate with the study PI [INVESTIGATOR_676835] a continuous basis and  will remove from the trial 
participant s with significant clinical deterioration or noncompliance of a type which could be 
dangerous. Criteria for removal from the study will include:  
1. Clinical deterioration which cannot be managed safely in the context of outpatient 
treatment. This would include a  participant who becomes suicidal, or a  participant 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 31 of 78 who goes on severe drug binges (including non -opi[INVESTIGATOR_162228]), endangering 
him/herself.  
2. Elevation of liver enzymes  > 3 times normal.  The PI  [INVESTIGATOR_1660] a study physician  is available 
24 hours/day by [CONTACT_17084]/or beeper in case of emergency.  
3. Participant becomes pregnant.  In case of incidental  pregnancy, the participant will 
remain in the study and will be followed until the resolution of  pregnancy. To reduce 
unneces sary procedures, we will stop PK blood draws, unless clinically indicated, 
however the safety monitoring will continue.  In addition, we will collect safety 
information related to the  pregnancy  and birth outcomes.  After finding an 
incidental  pregnancy  the removal of the implant will be offered to the participant and 
the participant will decide how best to proceed in consultation with her 
obstetrician.   The decision regarding the  pregnancy  will affect the decision whether or 
not to remove the implant at any  point during the  pregnancy. The risk of anesthesia 
differs during different times during  pregnancy, however the risks of anesthesia and 
the risks of removal are both minimal . 
If a participant becomes pregnant, PK labs will no longer be collected, but the participant will 
be followed for safety monitoring for the remainder of the study.  
For those who withdraw from the study, (data collection and / or treatment) there are two 
main options:  
Option 1:  Withdrawing from data collection and no further contact [CONTACT_676878] . 
This carries the least amount of risk, with option 2  carry ing some risk.  
Option 2:  Removal of the study medication via surgical procedure . Whilst removal of the 
study medication is straightforward in the early stages (up to about 10 days), 
removal after this becomes more complex as the OLANI biodegrades. Later 
procedures require a general anesthetic  (with access to OR facilities) and may 
result in a large scar – certainly larger than not removing the implant but the extent 
depends on the amount of tissue to be excised. The risks associated with general 
anesthetic  vary between people, but about 20% of those receiving general 
anesthesia  have min or AEs and 0.2% have major AEs including death. If removal 
of the implant is the only acceptable option to the participant, this will be arranged 
through either Columbia University Medical Center or another local hospi[INVESTIGATOR_307].  
 
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_676879] [INVESTIGATOR_38107]. If the 
study is prematurely terminated or suspended, the PI [INVESTIGATOR_676836] , 
(DSM B), FDA and will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant terminat ion or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, data quality are 
addressed ; and satisfy the Sponsor , NYSPI  [CONTACT_1744], DSMB  and FDA .  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 32 of 78 6 STUDY AGENT  
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  
6.1.1 Acquisition  
The OLANI will be sup plied by [CONTACT_676880].  
6.1.2 Formulation, Appearance, Packaging and Labelling  
[IP_ADDRESS]  Manufacturing and Sterility  
The OLANI is manufactured by [CONTACT_676881], [ADDRESS_915614], Subiaco, 
Perth, Western Australia, Australia 6008.  
Tel: +61 (0)8 93 88 1700, Email: [EMAIL_12937]  
The OLANI is manufactured under the code of GMP. Sterilization (gamma) validation of the 
product at 25KGy is performed in accordance with ISO [ZIP_CODE]. Implants are sterilized with 
gamma radiation between a minimum of 25KGy and no more than 40KGy. Regular crushed 
bioburden tests are also conducted on randomly selected samples from each batch. Pyrogen 
testing is also performed on sterilized product at routine periods.  
 
[IP_ADDRESS]  Packaging  
The OLANI is packed 10 pellets to one applicator device ( Figure 6.1 and Figure 6.2). The 
applicator device is then sealed in a small foil pouch –Figure 6.3. This small foil pouch is 
then in turn sealed in another larger foil pouch –Figure 6.4. The double foiled pouch and 
applicator is labeled with a gamma indicator dot and the product label and sent for gamma 
sterilization. The g amma indicator dot will turn red when exposed to gamma radiation.  
 
 
Figure 6.1: Applicator with OLANI pellets  

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 33 of 78  
 
Figure 6.2: Applicator with tablets exposed for delivery  
 
 
Figure 6.3: First layer packaging  
 
 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 34 of 78  
Figure 6.4: Second layer packaging  
 
[IP_ADDRESS]  Disposal  
The active implants shall be inserted into the subcutaneous tissue; however,  the applicator 
device will be removed during the procedure and should be disposed of as per standard 
clinical protocols for biological specimens. The packaging can be disposed of in general 
waste.  
 
6.1.[ADDRESS_915615] is supplied sterile in a double layer of foil packaging. Storage 
conditions require temperature to be maintained between 8 -30°C. Expi[INVESTIGATOR_676837] [ADDRESS_915616] will be prepared 
by [CONTACT_676882].  
 
6.1.5 Dosing and Admini stration  
All participants will be administered a double dose (two syringes with 10 tablets (1.8 g) each) 
of the OLANI ( ). Investigational product will be administered surgically by [CONTACT_676883] . Subcutaneous insertion of the investigational product shall be 
documented as time = 0 for the purposes of pharmacokinetic blood collection.  
 
6.1.6 Route of Administration  
Subcutaneous implant via small surgical procedure conducted under local anesthetic . 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 35 of 78  
6.1.7 Starting Dose and Dose Escalation Sc hedule  
All participants will be administered the same starting dose of 2 x OLANI ( , 1.8g).  
 
6.1.8 Dose Adjustments/Modifications/Delays  
Not applicable  
 
6.1.[ADDRESS_915617].  
 
6.1.11  Device Specific Considerations  
Not applicable.  
 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  
Go Medical will supply all study medication. The PI (or delegated study personnel) will sign 
that they have received all investigational product. Investigational product will be kept in a 
securely locked , temperature monitored cabinet  and a drug inventory maintained. All unused 
supplies must be accounted for and returned to the sponsor in the event it is not used.  
 
  

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 36 of 78 7 STUDY PROCEDURES AND SCHEDULE  
7.1 STUDY PROCEDURES/EVALUATIONS  
7.1.1 Study Specific Procedures  
[IP_ADDRESS]  Baseline Evaluation  
Baseline evaluation s will take place  at the SURC , with two screening assessments being 
carried out, followed by a recruitment visit . The nature of the study and its risks and benefits 
will be explained to the participant  by [CONTACT_978] [INVESTIGATOR_676838] a  written informed consent 
from each potential participant p rior to the administration o f any study -specific procedures. 
The most important aspects of the protocol such as the implant procedure are discussed in 
great detail . The PI [INVESTIGATOR_676839] d consent.  
At the first screening visit , informed consent for collecting information for screening will be 
obtained along with inclusion/ exclusion  criteria being assessed. The r esearch physician  will 
then perform tests as outlined in section 7.3.[ADDRESS_915618] blood 
and urine samples as outlined in section 7.3.2 .  
A recruitment visit will then be scheduled, where the research physician confirm s that a 
participant meets all incl usion/exclusion criteria, is medically healthy to participate in the 
study. The physician also reviews and signs the inclusion/exclusion checklist and signs off on 
enrollment documentation . A procedure note for the medical chart will be included and 
signed  verifying that the study physician reviewed results of the evaluation and obtained 
informed consent. Following study enrollment , the study physician assumes medical 
responsibility and arranging hospi[INVESTIGATOR_676840] (IP) administration at 
CUMC followed by [CONTACT_2360][INVESTIGATOR_676841] . 
 
[IP_ADDRESS]  Naloxone challenge test ( NCT ) 
All participants will undergo a NCT at SURC prior to IP administration. Prior to 
administration of the NCT, a baseline Clinical Opi[INVESTIGATOR_2573] W ithdrawal Scale (COWS ) assessment 
will be obtained. Participants will receive 0.[ADDRESS_915619] of these effects will wear off after 20 -30 minutes and 
treatment is usually not needed b ut in case of severe symptoms, participants will be offered a 
dose of clonidine 0.1 mg and/or clonazepam 0.[ADDRESS_915620] then they will progress to the IP administration with the 
implant ation  procedure  [IP_ADDRESS] .  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 37 of 78 [IP_ADDRESS]  Implantation Procedure  
The investigational product will be administered via a minor surgical procedure  conducted at 
CUMC  by [CONTACT_676884]. Christine Rohde  who is a board certified plastic surge on. 
Prior to the procedure participants will be fitted with an intravenous cannula to aid blood 
collection  during the first 48 hours of sampling . The surgical procedure will take 
approximately 30 minutes and will be performed under local anesthesia . The surgical 
procedure will be carried out by  [CONTACT_676885] (see 1.7) support ed by a clinical nurse and another support staff.  
 
Step 1:  Have the participant  lie on their ba ck on an appropriate operating table  
Step 2:  Disinfect hands with approved validated procedures for the institution where the 
procedure is being carried out then apply non -sterile gloves.  
Step 3:  Administration of intra -operative prophylactic antibiotic. There is good lit erature 
evidence for intra -operative prophylactic antibiotics with breast and other implants. 
For this reason , the participant  will be given 2g of IV cefazolin ( 600 mg clindamycin 
if allergic to cephalosporins or penicillin) within 30  minutes preceding the surgery.  
Step 4:  The participant’s abdomen is carefully observed and palpated with a view to defining 
the most ideal surgical site. The usual placement of the OLANI is  in V-shape (see 
Figure 7.1) with one implant on either side.  
 
 
Figure 7.1: Usual OLANI placement  
 
Step 5:  Using a new disposable marker pen, define the area that the local anesthetic  will be 
injected into ( Figure 7.2). The outer limit of the anesthetic is defined by [CONTACT_941] o uter lines 
and two single lines mark the center of the site. The two central lines guide the position 
that the original lidocaine is inserted into.  The outer lines indicate the area that the 
40 mL of bupi[INVESTIGATOR_676842].  

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 39 of 78 again  and puts on sterile gloves. The site should then be allowed to dry before 
surrounding the operative site with sterile towels or drapes.  
Step 9:  Surgical procedure  
The surgical procedure commences by [CONTACT_2329] a scalpel, blade size 15, where the skin 
at the center of the site is stretched and a 10 -12 mm incision approximately 1 -2 mm 
deep is created. This initial incision will simply be partially through the skin and so 
the blade is then reversed , and a firm incision is made approximately 5 -10 mm deep 
while the reverse blade is used to cut completely through the skin along the 10 -12 mm 
incision line.  
 
Note: The following part of the procedure is described for a right -handed  
surgeon.  
Step 10:  The surgeon uses their left hand to lift the subcutaneous tissues to the left of the [ADDRESS_915621] exposed with their left hand. The 
procedure is then repeated with the opposite hands when inserting the same forceps 
into the subcutaneous tissue on the participant’s right side of the abdomen.  
Pi[INVESTIGATOR_676843], ensuring that the syringe applicator is held correctly ( Figure 7.3). Do not 
open the back end of the device as there is a risk of tablets escapi[INVESTIGATOR_676844].  
 
Figure 7.3: Correct holding of syringe applicator  
 
 
 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 40 of 78 Note: The following description applies to a right -handed  surgeon inserting the 
first implant into the participant’s left side of the abdomen.  
Step 11:  The surgeon uses their left hand to li ft the subcutaneous tissues of the abdominal wall 
just 1 -2cm to the left of the incision. The bevel of the applicator should be facing 
upwards and the applicator is inserted carefully into the incision, e nsuring that the 
applicator is placed under the adip ose tissue but above the muscle sheath ( Figure 7.4) 
until firm resistance from the subcutaneous tissues is felt.  
 
Figure 7.4: Syringe applicator insertion  
 
Step 12:  Using the surgeons left hand it is then possible to push the subcutaneous tissues against 
the applicator until the applicator advances for 5 -10 mm. The surgeon’s left hand is 
then moved [ADDRESS_915622] above the sheath with a significant covering of subcutaneous 
tissues above the applicator. The applicator’s trocar can then be pi[INVESTIGATOR_676845]’s  right hand and the opening of the applicator’s rear cap can then occur 
providing the participant is leaning a little to the left so that there is no risk of tablets 
being lost from the applicator. The trocar is then inserted firmly ( Figure 7.5) so that 
the tablets are slowly pushed forward while the applicator is slowly withdrawn.  

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 41 of 78  
Figure 7.5: Insertion of OLANI using Syringe plunger  
 
If this is carried out carefully then tablets will be in a line rather than pushed into one 
ball ( Figure 7.6). It is preferable that the tablets be pushed gen tly in a line to ensure 
correct placement.  
 
Figure 7.6: Correct positioning of OLANI  
 
Step 13:  The procedure is then repeated through the same incision using a second applicator 
syringe to position the OLANI tablets on the other side of the abdomen.  The site of 
each OLANI’s will be recorded on the CRF.   
Step 14:  Closure of the incision  
It is important that closure be carried out in two layers. The first involves closure of 
the subcutaneous tissues. This should usually be carried with an absorbable suture. 
We recommend a 3 -0 monocryl or biosyn deep dermal suture layer. The second layer 
of closure requires the skin to be closed using a cyanoacrylate medical glue. In the 
practical care of those with addictions the glue has proved to be very acceptable as 

A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915623] the risk of a stitch abscess. Following the application of glue, steri -strips are 
applied , and the wound is covered with a dressing.  
[IP_ADDRESS]  Wound Site/Implant Site Assessment  
[IP_ADDRESS].1  SURC Clinic  (Initial 48 hours)  
Wound Site/Implant Site Assessment will be carried out by  [CONTACT_9154] [INVESTIGATOR_124]. Bisaga (trained  
in the evaluation  by [CONTACT_676886]. Rohde ), using the Implant Site Evaluation Form 
(ISEF) . The wound/implant site will be assessed  at 24 2 hours and 48 hours 2 hours  after 
the procedure  and more frequently if clinical indicated. Any concerns that are identified by 
[CONTACT_676887] 7.6.2 .  
 
[IP_ADDRESS].2  Clinilabs Clinic  (Post 48 hours)  
Wound Site/Implant Site Assessment will be carried out by a research nurse (trained by [CONTACT_676888]. Rohde), using the ISEF  as per the protocol time points outlined in Table 
7-1. Any concerns that are identified by [CONTACT_676889] 7.6.2 . The Clinilabs doctor will consult with the 
study surgeon if required.  
If there are any concerns to the wound/implant si te by [CONTACT_2299] s outside of regular 
study visits, they will be asked to come to the Clinilabs clinic  for evaluation  as above . All 
evaluations  will be documented  using the ISEF .  
Note: As appropriate, participants may be seen for follow -up visits a t the SURC  clinic  (i.e. if 
clinically indicated  or if traveling to the Clinilabs clinic  presents a hardship to a participant) . 
 
7.2 LABORATORY PROCEDURES/EVALUATIONS  
7.2.[ADDRESS_915624], 4.5  mL of blood will be collected in 1 tube  (lavender top EDTA tube) : 
• [FBC] Full Blood Count : RBC, WBC, Hematocrit, Hemoglobin, Platelet Count, 
Eosinophils, Basophils , Monocytes, Neutrophils, Lymphocytes, Mean Corpuscular 
Volume (MCV), Mean Corpuscular H emoglobin Concentration (MCHC), Mean 
Corpuscular Hemoglobin (MC H), Reticulocytes , Red cell distr ibution width (RDW), 
immature granulocytes  
 
For the following tests, 5  mL of blood will be collected in 1 tube (red/grey mottled  top gel 
barrier SST  tube): 
• [FCP] Full Chemistry  Panel  with Liver Function Tests : Glucose, Uric Acid , Blood 
Urea Nitrogen (BUN) , Creatinine , Sodium , Potassium , Chloride , Calcium , 
Phosphoru s, Protein Total , Albumin , Globulin , Albumin/Globulin A/G Ratio , 
Bilirubin (total) , Bilirubin (direct) , Bilirubin (indirect) , Alkaline Phosphatase , Lactate 
Dehydrogenase (LDH) , AST (SGOT) , ALT (SGPT) , GGT , Iron, Total Cholesterol , 
Triglycerides , HDL Cholesterol , LDL Cholesterol (calculated) , Magnesium , CO2 , 
CPK , Amylase , Lipase  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 43 of 78 For the following tests, 5  mL of blood will be collected in 1 tube  (lavender top EDTA tube) : 
• Hepatitis A  IGG 
• Hepatitis B Serology  
• Hepatitis C Serology  
 
For the following test, 5  mL of blood will be collected in 1 tube  (red/grey mottled  top gel 
barrier SST  tube): 
• HIV Serology  
 
For the following tests, a sample of urine is collected:  
• UA (Urinalysis ) including urine color, appearance, bilirubin, urobilinogen, WBC 
esterase and a microscopic examination (WBC, RBC, epi[INVESTIGATOR_1663], mucus threads, 
bacteria)  
• LEU (Leucocytes), NIT (Ni trite), PRO (Protein), pH, BLD (Blood), SG (Specific 
Gravity), KET (Ketones), GLU (Glucose)  
• [UDS ] Full drug screen including  morphine, oxycodone, methadone, cocaine, 
amphetamines, hydromorphone, hydrocodone, codeine, methamphetamines, thc, 
benzodiazepi[INVESTIGATOR_1651],  fentanyl  and buprenorphine assay.  
 
Pregnancy test : For all female participants, a blood test is done initially, with urine tests 
done monthly afterwards. A blood test will be used to confirm  a positive urine result.  
 
7.2.2 Other Assays or Proced ures 
[IP_ADDRESS]  Naltrexone Blood Level Assay  
9 mL of whole blood will be collected into 10cc Na Heparin (green  top) tubes  (see Section 
[IP_ADDRESS]  for more details  regarding the procedure ). 
 
7.2.3 Total amount of Blood to be collected  
The amount of blood drawn for the study is:  
• HIV and Hep atitis  screening = 10 m L. 
• FCP and FBC = 180.5  mL (18 x  9.5 m L) 
• Pregnancy testing (Female participant s only) = 4  mL (during the trial, a blood test will 
be used to confirm a positive urine result)  
• Total blood samples for naltrexone / naltrexol = 288 m L (32 x 9 m L) 
• There is also the potential for further bloods  to be taken on any un -scheduled visit for 
PK bloods ( 10 mL) and follow -up visit for outstanding AEs ( FCP and FBC 9.5  mL) 
post end of trial.  
 
Note:  that the total blood samples for naltrexone / naltrexol have been calculated for the 
worst case of participants going out to Day 540. In the event that a participant registers two 
consecutive monthly naltrexone blood levels recorded at <0.1  ng/mL, then the participant will 
be withdrawn from the study and the blood collection will be reduced by 10 mL for every 
monthly time point not required.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 44 of 78 7.2.4 Specimen Preparation, Handling and Storage  
[IP_ADDRESS]  Naltrexone Blood  Level Assay  
All naltrexone blood samples will b e collected in 1 x 10  mL Na Heparin tubes (9  mL) and 
stored in the refrigerator at 0 -4°C until  specimen  preparation.  Specimen preparation will be 
carried out within 30 minutes of collection . This will involve centrifugation of the blood 
sample  in an ambien t centrifuge for 15 min at 2,000 rpm within 30 minutes of collection  to 
enable plasma separation. The plasma will be  extracted and  transferred into two 2  mL 
cryovials (2 aliquots total) . Cryovials  with a liquot will be stored in a freezer at no 
warmer than -70°C until shipment . 
All plasma samples up to  48 hours will be collected, processed and stored at NYSPI. All 
plasma samples scheduled after 48 hours will be collected, processed and stored at Clinilabs.  
When batches of greater than 50 samples are available  these can then be  shipp ed on dry ice to 
the PK analysis  laborator y for free (unconjugated) naltrexone and free (unconjugated) 6 -β-
naltrexol analysis. Backup samples will remain stored at Clinilabs  and NYSPI  [INVESTIGATOR_676846] .  
 
7.2.5 Specimen Shipment  
Plasma will be stored for batch shipment to the PK analysis  laborator y for analysis. Storage 
of samples at  no warmer than  -70°C will be done at Clinilabs  and NYSPI . Shipment of 
samples to the PK laborator y will be done under dry ice.  
 
7.3 STUDY SCHEDULE  
7.3.1 Screening  Visit 1  
Participant  shall be screened for inclusion and exclusion criteria and overall suitability for the 
study.   
• Obtain informed consent for screening.  
• Review medical history to determine eligibility based on inclusion/exclusion criteria.  
• Review medications history to dete rmine eligibility based on inclusion/exclusion criteria.  
• Perform medical  and psychiatric examinations , including Patient  Health Questionnaire 
(PHQ) and Beck Depression Inventory  (BDI-II), MINI -International Neuropsychiatric 
Interview (MINI),  needed to determine eligibility based on inclusion/exclusion criteria.  
• Concomitant medication review . 
• Physical (Record  BMI) and mental status  exam.  
• Vital signs . 
• A [ADDRESS_915625] 
operating procedures and will be assessed by a qualified  clinician.  
• C-SSRS -Lifetime . 
• Breathalyzer  Assessment  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 45 of 78 7.3.2 Screening  Visit 2  
Review of  inclusion and exclusion criteria and overall suitability for the study.  
• Collect blood for FB C, FCP. 
• Collect urine for UA, and UDS . 
• Collect blood for Hepatitis and HIV tests . 
• Collect blood for baseline naltrexone and 6 -β-naltrexol measurement.  
• Collect blood for pregnancy test in female participants . 
• Self-reported substance use  (using the Recent Drug Use -Baseline [RDU]) . 
• Concomitant medication review.  
• AE Monitoring.  
 
7.3.[ADDRESS_915626];  
• Review of screening assessments and study inclusion exclusion criteria. All screening 
assessments must be collected within 30 days  prior to  the Recruitment  visit, 
• Obtain informed consent for IP administration . 
• Concomitant medication review . 
• AE Monitoring . 
• Breathalyzer  Assessment  
 
7.3.4 Day -1 to Day 2 ( ‘Admission ’ Days)  
[IP_ADDRESS]  Admission Day -[ADDRESS_915627] to confirm opi[INVESTIGATOR_676847] . 
 
[IP_ADDRESS]  Admission Day 0 
Participants will be scheduled for administration of the OLANI as outlined in section [IP_ADDRESS] . 
After a review of concomitant medications and vital signs are obtained, participants  will be 
fitted with the iv cannula to aid in the collection of blood sample for the first [ADDRESS_915628] the blood analysis of 
naltrexone and 6 -β-naltrexol . Processing and storage of blood samples shall be done as per  
section [IP_ADDRESS] . 
The recorded dose time (0 hour) will be the time at which the procedure will be completed. 
Naltrexone blood samples (see section [IP_ADDRESS] ) will be collected at the following time points: 
3 hours 60 min, 6 hours 60 min, and 12  hours 60 min. The actual time of each PK sample 
collection shall be recorded . 
Participants will also be monitored for AEs.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 46 of 78 [IP_ADDRESS]  Admission Day 1 
Naltrexone blood samples (see section [IP_ADDRESS] ) will be co llecte d at 24  hours [ADDRESS_915629] a Wound Site/ Implant Site Assessment  as per [IP_ADDRESS] . 
At this time, participants will have t he option of remaining an inpatient or being discharged 
from the SURC clinic and returning for the 48 -hour observation (Admission Day  2). 
 
[IP_ADDRESS]  Admission Day 2 
Naltrexone blood samples (see section [IP_ADDRESS] ) will be collecte d at 48 hours [ADDRESS_915630] a Wound Site/ Implant Site Assessment  as per [IP_ADDRESS] . 
Remaining inpatient participants will be discharged from the SURC clinic . 
All participants will be provided with a timetable for their follow -up visits, which will be 
carried out at the Clinilabs  clinic.  
7.3.5 Follow -Up Day 4  to 540 
Participants will be instructed to attend the Clinilabs  clinic  to continue study procedures on 
an outpatient basis as per the protocol time points outlined in  Table 7-1. There are allowable 
variations in actual day of collection as long as the variation is recorded. The following will 
be collected at all time points: Concomitant medical review, PK blood collection, AE 
monitoring, vital signs ( Blood pressure, heart rate, respi[INVESTIGATOR_697], and oral body 
temperature)  and a Wound Site/Implant Site assessment ( see section [IP_ADDRESS] ).  
The following will also be collected on day 28 and the n monthly as outlined in Table 7-1, 
PHQ &  BDI-II, C-SSRS , FBC, FCP,  UA, Pregnancy test (initial with urine with serum 
testing used to confirm positive results) , substance use reporting  (self-report  using the 
Quantitative Substance use Inventory ) and UDS.  
Note: As appropriate, participants may be seen for follow -up visits at the SURC clinic (i.e. if 
clinically indicated  or if traveling to the Cli nilabs clinic  presents a hardship to a participant) . 
SARS -CoV -2 Note:  This study is being conducted in [LOCATION_001], NY; a location heavily  
impacted by [CONTACT_25963] -19 pandemic. Therefore, for the safety of study participants, the IRB 
requested  on 21 April 2020  that in -persons study visits be stopped and replaced with 
telephone or video visits. Thus, where in -person study visits are not possible, safety will be 
monitored remotely. This change means that for some participants, certain procedures (e.g. 
PK blood draws), may be missed during the time of the public health emergency. Table 7-1 
has been updated to indicate which  procedures will be c aptured by [CONTACT_756]/video visits and 
which  procedures may be missed due to COVID -19. In case there are safety concerns that 
need in -person evaluation to determine best course of action, such as new -onset implant site -
reaction or site drainage, then an in -person visit at the clinic will be conducted.  
 
This change was implemented on 27 April 2020 and all missed visits/procedures are being 
tracked. In person visit will resume immediately when deemed safe and appropriate by [CONTACT_5040].  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915631] been obtained, or after Day 540 visit has occurred.  
7.3.7 Early Termination Visit  
Any participant s that are withdrawn will be required to attend the SURC  clinic for a n early 
termination /withdrawal visit as outlined in Table 7-1. Participant s will be advised of their 
options as outlined in in section  5.4.[ADDRESS_915632] on -study visit: ongoing AEs, SAEs regardless of attributability, any laboratory 
abnormalities co nsidered to be AEs or potentially harmful to the participant. For in -clinic 
follow -up visits, assessments performed should reflect what is considered medically 
necessary to assess the event(s).  
7.3.[ADDRESS_915633] totals for analysis.  
Participants  will be asked to complete the following; vital signs, concomitant medication 
review, wound site/implant site assessment and AE monitoring  (see Table 7-1). Additional 
assessments performed at Unscheduled visits are at the discretion of a study physician.  
 
7.3.[ADDRESS_915634] monthly PK visit 540 days, if the 
participant has detectable naltrexone p lasma levels. Follow -up visits will continue until two 
consecutive monthly naltrexone blood levels recorded at <0.1  ng/mL  are received from the 
lab and recorded. If the latest PK levels are pending, participants will continue to make 
follow -up visits  (see Table 7-1). 
7.3.[ADDRESS_915635] on -
study visit  (see Table 7-1). An in -clinic follow -up visit must be conducted [ADDRESS_915636] on -study visit: ongoing AEs, SAEs regardless of 
attributability, any laboratory abnormalities consid ered to be AEs or potentially harmful to 
the participant. For in -clinic follow -up visits, assessments performed should reflect what is 
considered medically necessary to assess the event(s) . All other participants that will have 
additional questions or conc erns about the fate of the implant will also be encouraged to 
come for a follow -up meeting with a study physician.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 50 of 78 12. Satellite Location 1  = Columbia University Medical Center  (CUMC) , [ADDRESS_915637]., [LOCATION_001], NY [ZIP_CODE], [LOCATION_003]  
13. Satellite Location 2  = Clinilabs,  [ADDRESS_915638], [LOCATION_001], [ZIP_CODE] for all visits after the initial 48 -hour time -point  
14. Changes Due to COVID -19: During the public health emergency, some of the monthly follow -up visits may occur by [CONTACT_756]/video only. The following safety assessments will occur during 
these remote study visits: concomitant medication review, PHQ (BDI -II), C -SSRS1 (since last visit ), AE monitoring, Qualitative Substance Use Inventory  and wound site/implant site assessment 
(self-reported ) done via video link , if possible . Conversely, t he following assessments/procedures may be missed  because of having remote study visits : safety labs, PK blood collection, pregnancy 
test, urine drug screen, vital signs/weight.   
15. Unscheduled Visits:  Vital signs, concomitant medication review, wound site/implant site assessment and AE monitoring are to occur at all Unscheduled Visits. Additional assessments performed 
are at the discretion of a study physician.  
16. Vital Signs:  Blood pressure, heart rate, respi[INVESTIGATOR_697], and oral body temperature will be measured after the subject has been in a seat ed posit ion for at least 5 minutes.  
Note:  After a subject’s last visit, the Disposition CRF  must be completed.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 51 of 78 7.4 CONCOMITANT MEDICATIONS, TREATMENTS AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on 
the case report forms (CRFs). For this protocol, a prescription medication is defined as a 
medication that can be prescribed only by a properly authorized/licensed clinician. 
Medications to be reported in the CRF are conco mitant prescription medications, over -the-
counter medications and non -prescription medications.  
 
7.5 PROHIBITED MEDICATIONS, TREATMENTS AND PROCEDURES  
The medications and substances listed below are prohibited for the specified time periods:  
• Buprenorphine , either as part of a maintenance program  or any illicit/non prescribed is 
prohibited for the duration of the study.  
• Methadone  is prohibited at least 14 days prior to Day 0 and for the duration of the Study.  
• All other opi[INVESTIGATOR_676848] o f the study  unless approved by [CONTACT_978] [INVESTIGATOR_676849] (see section 7.7)  
• Oral naltrexone  is prohibited for at least 30 days prior to Day 0 and for the duration of 
the study  
• Other forms of extended release naltrexone (e.g. Vivitrol)  is prohibited for at least 
24 months  prior to Day 0 and for the duration of the study  
 
7.6 PROPHYLACTIC MEDICATIONS,  TREATMENTS AND PROCEDURES  
7.6.1 Prophylactic Medications  
One dose of IV antibiotic  within 30 minutes of the surgical procedure is given  as part of the 
implantation procedure ( [IP_ADDRESS] ): 
2g cefazolin IV  If allergic  to cephalosporins or penicillin , then alternative  is 600 mg 
clindamycin  
7.6.2 Management of Infection/  Inflammatory Responses to the Wound/Implant Site  
All Participant s will have their  wound site / implant site regularly assessed as per [IP_ADDRESS]  for 
signs of infection and/or inflammatory reactions . Particular attention shall be paid during 
follow -up visits at day 4, 8, 14 and 21 (as per 7.3.11 ) for signs  of infection  to the wound site 
or early signs of an inflammatory reaction to the implant. Symptoms and signs relating to 
redness, excessive itchiness and/or increasing pain at the implant  or wound site may be 
attributed to the inflammatory response . Symptoms relating to edema, spreading cellulitis, 
fever and general feeling of malaise are likely to be attributed to infection of the implant or 
wound site. Inflammatory reactions tend to occur much more frequently than infections. 
Treatment for inflammatory reactions or i nfections should be performed as specified below.  
 
Infection treatment protocol  
Infections present in participant s as spreading cellulitis with other clinical indicators such as 
fever or general malaise.  Spreading cellulitis involves redness of the skin which may extend 
several c entimetres  around the wound and extend over the area of the implant. Participant s 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 52 of 78 with spreading cellulitis should be treated immediately with antibiotics (e.g., cephalexin) with 
physical exam and/or laboratory results used to mon itor treatment response. If the infection 
does not resolve with oral antibiotics, a course of IV antibiotics may be necessary.  
 
Inflammatory responses without an infection  
Signs of redness, swelling, tenderness, itchiness or pain as identified from the IS EF after day 
14 without the presence of fever or general feeling of malaise, suggests the onset of a mild 
inflammatory response  to the implant only and  the treatment regime described below (level 1 
to level 4) should be implemented.  
 
Level 1 treatment (25  mg prednisone)  
Participant s should be  prescribed prednisone  at [ADDRESS_915639] not improved after 3 days then participant s 
shall progress to Level 2 treatment.  
 
Level 2 treatment (50  mg prednisone)  
If Level [ADDRESS_915640] not improved, then participant  shall progress to Level 3 
treatmen t protocol.  
 
Level 3 treatment (betamethasone and fluid assessment)  
Participant s who have failed to respond to Level 2 treatment, shall stop  their oral prednisone  
and be given an injection of betamethasone, with 1  mL diluted in saline or local anesthetic 
(1% lidocaine, 3mL) injected around the implant site where inflammation is occurring in the 
absence of fluid build -up.   
 
If there is fluid present prior to the betamet hasone injection, the fluid must be aspi[INVESTIGATOR_3831]. To 
achieve aspi[INVESTIGATOR_676850], a needle with a wide bore is required to aspi[INVESTIGATOR_676851] -like fluid. The aim of the drainage is to a) relieve tension and b) 
remove the fluid bu ild-up. It is therefore important to lavage the fluid space until a CLEAR 
ASPI[INVESTIGATOR_676852]. Lavage the space with normal saline or Hartman's solution. This 
normally requires multiple lavages, usually about 10m L each time. The final drainage(s) 
is/are p erformed without suction, to avoid dislodging/damaging the implant. Drainage and 
lavage are followed with a brief course of oral prophylactic antibiotic.   
   
Where there are two implant sites, a second injection will be required for the second site (if it  
is also affected by [CONTACT_676890]). The participant s should rest for [ADDRESS_915641].  
Note: betamethasone should not be substituted for any other steroidal injection with an 
alcohol base carrier as this will affect the implant composition.  
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915642] slightly 
improved but not fully resolved a second round of betamethasone injections can be 
commenced.  
 
Level 4 treatment (removal of implants)  
In participant s that do not respond adequately to the treatment regime, the implant(s) should 
be surgically removed. This can be achieved by a surgical incision over the implant site and 
should be done by [CONTACT_676891].  
 
Inflammatory response with seconda ry infection  
Some participant s will develop fluid around their implant as an inflammatory response to the 
implant. The build -up of fluid causes pressure and symptoms such as pain which can result in 
the fluid tracking through the line of least resistance a nd be expelled through the initial 
surgical incision.  This can lead to the wound opening and the risk of secondary infection, as 
well as implant expulsion. If  the implant and wound site is treated according to level [ADDRESS_915643] of the wounds close within a few days of the treatment resulting in the process settling 
as the fluid drainage no longer keeps the wound open.  If the infection is not resolving after 3 
days of oral antibiotics , then IV antibiotics should be introduced. In participant s that do not 
respond adequately to the treatment regime, the implant(s) should be surgically removed. 
This can be achieved by a surgical incision over the implant site and should be done by [CONTACT_676892].  Antibiotics shall be continued after surgical removal to treat the 
remaining infection until all symptoms have resolved.  
 
7.[ADDRESS_915644] such as buprenorphine.  
 
7.8 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  
N/A 
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 54 of 78 7.9 REIMBURSEMENT COSTS  
Participants will receive  reimbursement as follows.  
• $50 for each of the two screening visit (2 visits ) 
• $50 for the consent visit (1 visit)  
• $400 for Day -1 to Day 2, the Admission Days (either 1 or 2 visits ) 
• $50 for each scheduled outpatient visit  (25 visits ). Participants will receive an additional 
incremental bonus  of $10 for each  subsequent visit attended  (Visit 1: $50, visit 2: 
$50+$ 10, Visit 3: $50 +$20, Visit 4: $50 +$ 30 …) . In case the scheduled visit is missed 
the value of the bonus is reset to the starting value of $ 10. This schedule is designed  to 
reinforce adherence to all study safety assessments. Participants will not be penalized for 
missed visits during the COVID -19 pandemic as long as they attend telephone/video 
visits in place of the scheduled clinic visit .  
• Travel reimbursements – in addition to the amounts specified above, participants will 
receive $20 for travel at each visit, and up to $50 in travel if participants provide receipts.  
The total amount of reimbursement should a participant attend every scheduled visit is $4,800 
plus a maximum of $15 00 in travel reimbursements depending on provided receipts .  
If a participant is required to return for furthe r PK or AE follow -up visits, then they will 
receive $50 plus the incremental bonus , plus $20 for travel, or up to $50 in travel if 
participants provide receipts.  
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 55 of 78 8 ASSESSMENT OF SAFETY  
8.1 SPECIFICATION OF SAFETY PARAMETERS  
Safety will be assessed on the basis of:  
• the incidence of death  
• the incidence of SAE s 
• the incidence AEs leading to discontinuation  
• the incidence common AEs 
• the incidence complications of insertion  
• the incidence implantation site reactions  
• laboratory abnormalities indicating hepatic p roblems (absolute values and changes over 
time)  
 
8.1.1 Definition of Adverse Events (AE)  
AEs will be identified from the telephone interviews, face to face visits or from the CRF. 
They will be recorded on an AE form.  
Definitions  
An AE is any untoward medical oc currence in a clinical investigational participant 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable  or unintended sign 
(including an abnormal laborat ory finding), symptom, or disease temporally associated with 
the use of a medicinal investigational product, whether or not considered related to the 
medicinal product. An adverse event is any adverse change (developi[INVESTIGATOR_255931]) from 
the patient’s pre -treatment condition, including concurrent illness.  
The investigator must make the distinction between exacerbation of pre -existing illness and 
lack of therapeutic efficacy.  
 
8.1.2 Definition of Serious Adverse Events (SAE)  
A SAE is any adverse experience occurring during the study period that:  
• results in death;  
• is life -threatening;  
• results in inpatient hospi[INVESTIGATOR_869] ; 
• results in a persistent or significant disability/incapacity; or  
• results in congenit al anomaly/birth defect.  
A life-threatening  AE is one that actually places the participant at immediate risk of death. A 
participant ’s reaction is not classified as life -threatening simply because more severe 
manifestations of the same adverse reaction can  be fatal, e.g. mild airway obstruction is not 
life threatening but severe airway obstruction is.  
Hospi[INVESTIGATOR_676853], any transfer within a hospi[INVESTIGATOR_676854] (for example, transfer of a  participant from a p sychiatric unit to a 
general medical unit) and prolongation of admission. Prolongation of hospi[INVESTIGATOR_144104] 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 56 of 78 defined as any extension of an inpatient hospi[INVESTIGATOR_676855]/ required 
in relation to the original reason for the initial admission, as determined by [CONTACT_101831].  
Study coordinators will report any new SAEs to the PI, NYSPI [CONTACT_1744], DSMB  and sponsor 
within [ADDRESS_915645] knowledge.  
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
8.2.1 Severity of Event  
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s 
daily activities.  
• Moderate  – Events result in a low level of inconvenience or concern with  the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  
 
8.2.2 Relationship to Study Medication and Surgical Procedure  
The clinician’s assessment of an AE's relationship to the study medication (i.e. OLANI) or 
the surgical procedure  is part of the documentation process, but it is not a fac tor in 
determining what is or is not reported in the study. If there is any doubt as to whether a 
clinical observation is an AE, the event should be reported. All AEs must have their 
relationship to study agent assessed. In a clinical trial, the study prod uct must always be 
suspect. To help assess, the following guidelines are used.  
• Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnorma l 
laboratory test result, occurs in a plausible time relationship to drug administration and 
cannot be explained by [CONTACT_9153]. The response to 
withdrawal of the drug (dechallenge) should be clinically plausible. The eve nt must be 
pharmacologically or phenomenologically definitive, with use of a satisfactory 
rechallenge procedure if necessary.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence 
of other factors is unlikely. The clinica l event, including an abnormal laboratory test 
result, occurs within a reasonable time after administration of the drug, is unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and follows a clinically 
reasonable response on withdra wal (dechallenge). Rechallenge information is not 
required to fulfil this definition.  
• Possibly Related – There is some evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the trial medication). 
However, other factors may have contributed to the event (e.g., the participant’s clinical 
condition, other concomitant events). Although an AE may rate only as “possibly related” 
soon after discovery, it can be flagged as requiring more infor mation and later be 
upgraded to “probably related” or “definitely related,” as appropriate.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 57 of 78 • Unlikely to be related – A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to drug administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administration of 
the trial medication) and in which other drugs or chemicals or underlying disease 
provides plausible explanations (e.g., the participant’s clinical cond ition, other 
concomitant treatments).  
• Not Related – The AE is completely independent of study drug administration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an 
alternative, definitive etiology documented  by [CONTACT_15370].  
 
8.2.3 Expectedness  
[IP_ADDRESS]  Adverse Drug Reactions Commonly Seen from  Naltrexone (MIMS)  
• Difficulty sleepi[INVESTIGATOR_007]  
• Anxiety  
• Nervousness  
• Abdominal pain/cramps  
• Nausea and/or vomiting  
• Low energy  
• Join and muscle pain  
• Headache  
• Loss of appetite  
• Diarrh ea 
• Constipation  • Increased thirst  
• Increased energy  
• Depressive mood  
• Irritability  
• Dizziness  
• Skin rash  
• Delayed ejaculation  
• Erectile dysfunction  
• Reduced sexual desire  
• Chills
 
[IP_ADDRESS]  Adverse Events  Commonly Seen Following Implantation procedure  
• Local inflammatory reaction; itchiness, redness, heat or swelling  
• Wound site Infections  
• Hematoma  
 
[IP_ADDRESS]  Adverse Events Rarely Seen Following Implantation procedure  
• Allergic reactions to suture material  
• Implant removal for infections or allergic responses  
• Implant removal for psychological reasons.  
 
[IP_ADDRESS]  Adverse  Events Commonly Seen from Poly Lactide Polymer  
• Local inflammatory reaction; itchiness, redness, heat or swelling  
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 58 of 78 8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND 
FOLLOW -UP  
The occurrence of an AE or SAE may come to the attention of study personnel during study 
visits and interviews of a study participant presenting for medical care, or upon review by a 
study monitor.  
All AEs including local and systemic reactions not meeting the criteria for SAEs will be 
captured on the appropriate CRF. Information to be collected includes event description, time 
of onset, clinician’s assessment of severity, relationship to study product (assessed only by 
[CONTACT_8703] a diagnosis), and time of resolution/ stabilization  
of the event. All AEs occurring while on study must be documented appropriately regardless 
of relationship. All AEs will be followed to adequate resolution.  
Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s 
condition deteriorates at any time during the study, it will be recorded as an  AE. 
Changes in the severity of an AE will be documented to allow an assessment of the duration 
of the event at each level of severity to be performed. AEs characterized as intermittent 
require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_676856] 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of 
study participation. At each study visit, the investigator will inquire about t he occurrence of 
AE/SAEs since the last visit. Events will be followed for outcome information until 
resolution or stabilization.  
In the event of study discontinuation for any reason, any ongoing AEs will be followed until 
resolution, or in the event of re moval of the OLANI for at least [ADDRESS_915646] on the ethical acceptability of the  trial. 
Investigator shall report all AE’s on a monthly basis to sponsor and Data Safety Monitoring 
Board  (DSMB ) for review.  
The sponsor will update the Investigator Brochure regularly with any new safety information 
relating to the drug.  
 
8.4.2 Serious Advers e Event Reporting  
All SAEs should be reported immediately to the sponsor,  NYSPI  [CONTACT_1744], FDA , DSM B except 
for those SAEs that the protocol or other document (e.g. Investigator's Brochure) identifies as 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 59 of 78 not needing immediate reporting. The immediate reports should be followed promptly by 
[CONTACT_12908], written reports. The immediate and follow -up reports shoul d identify participants by 
[CONTACT_676893]' names 
personal identification numbers, and/or addresses.  
 
[IP_ADDRESS]  Management of SAE’s  
SAEs, as defined by [CONTACT_1622], will be systematically evaluated  at each clinic visit. Any SAE, 
whether or not related to study medication, will be reported to the  NYSPI [CONTACT_1744], FDA  & 
DSMB . The initial SAE report will be followed by [CONTACT_63664] a completed SAE report to 
both institutions.  
In the event that a  participant  either withdraws from the study or the investigator decides to 
discontinue a  participant due to SAE, the  participant will have appropriate follow -up medical 
monitoring. Monitoring will continue until the problem requiring hospi[INVESTIGATOR_676857], is clearly unrelated to study medication, or 
results in death. Outcome of SAEs will be reported to the NYSPI [CONTACT_1744], FDA  & DSMB  as 
soon as this information becomes available. A summary of the SAEs that occurred during the 
previous year will be included in the annual progress report to the NYSPI [CONTACT_1744], FDA  & 
DSMB . 
 
8.4.[ADDRESS_915647] the decision whether or not to remove the 
implant at any point during the  pregnancy. The risk of anesthesia differs during different 
times during  pregnancy, however the risks of anesthesia and the risks of removal are both 
minimal.  
 
8.5 STUDY HALTING RULES  
8.5.1 Study Termination  
The Sponsor reserves the right to close the investigational sites or terminate the study at any 
time. The Investigator may initiate site closure at any time, provided there is reasonable 
cause and suffic ient notice is given in advance of the intended termination. Reasons for the 
early closure of an investigational site by [CONTACT_343884], or termination of a 
study by [CONTACT_1034], may include but are not limited to:  
• failure of the Investigator  to comply with the protocol, the Sponsor’s procedures, or 
GCP guidelines  
• safety concerns  
• inadequate recruitment of participants by [CONTACT_676894], NYSPI  [CONTACT_1744], DSMB  and FDA . 
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 60 of 78 8.5.2 On-Site Audits  
Representatives of the Spon sor’s quality assurance department may visit the site to carry out 
an audit of the study in compliance with regulatory guidelines and the Sponsor’s standard 
operating procedures. Audits and clinical trial monitoring will also be carried  out by [CONTACT_207418], Clinilabs during the trial period.  These audits will require access to all study records, 
including source documents, for inspection and comparison with the CRFs. Participant  
privacy must, however, be respected. Similar auditing procedures may  also be conducted by 
[CONTACT_676895] a regulatory 
submission. The Investigator should immediately notify the Sponsor if they have been 
contact[CONTACT_426] a regulatory agency conc erning an upcoming inspection.  
 
8.6 DATA AND SAFETY MONITORING PLAN ADMINISTRATION  
8.6.1 Responsibility for data and safety monitoring  (DSM)  
The study PI, [CONTACT_676908], is required to be present for all DSMB meetings to provide 
reports for all accumulated data from the trial. The PI [INVESTIGATOR_676858] . The PI [INVESTIGATOR_676859]. Edward Nunes, study Medical Monitor.  
 
8.6.2  Frequency of DSM  
Ongoing data  and safety  monitoring  will be conducted  weekly  during  research team  meetings 
of the PI [INVESTIGATOR_676860].  Every  three months,  the PI  [INVESTIGATOR_676861] s enrolled,  the number  who completed  the protocol,  the 
number  who dropped  out of the protocol  prior  to completion  (and reason  why),  any AEs, 
procedures  for assuring  participants  privacy  and confidentiality,  and the quality  and integrity  
of the data collected.   Corrective  action  will be taken  if needed.  IRB study protocols  and 
informed  consent  documents  will be reviewed  annually  by [CONTACT_1201]. Reports of  enrollment  
and retention  and reporting  of AEs are required  with these  renewals.   
 
In addition,  all studies  involving  human  participant s are periodically  and systematically  
reviewed  by [CONTACT_676896] . These  procedures  assure  protocol  
compliance  by [CONTACT_676897]'  research  charts,  comparing  
research  charts  to the IRB protocol. All SAEs  will be  reported  to the FDA (as appropriate) 
and the DSMB  in a timely  fashion.  
 
A separate  DSMB  (See 8.6.3  for details)  will meet  quarterly and within a week of any SAEs  
occurring. Ad hoc meetings may also occur if any study related issues arise during the course 
of the stud y. 
 
8.6.[ADDRESS_915648]. Jonathan Stewart  a Professor of Psychiatry at Columbia 
University College of Physicians and Surgeons a nd a senior expert in mood disorder 
pharmacotherapy. Three additional faculty members from the division will join the DSMB;  
• [CONTACT_676909].D, a senior researcher in the division, with more than 30 years of 
experience in the early phases of medicati on development for substance use disorders;  
• [CONTACT_676910], an opi[INVESTIGATOR_676862], and  
• [CONTACT_257510] R. Williams, another research psychiatrist in the division.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915649] 
pertaining to the study. The DSMB will prepare a report in response to any SAE review 
meetings and will submit a DSM report annually. Reports will be submitted to the Sponsor 
and other authorities as appropriate. This report  will include  the following:  
a) Brief  description  of the trial,  
b) Baseline  socio -demographic  characteristics,  
c) Retention  and disposition  of study  participants,  
d) Quality assurance issues,  
e) Regulator y issues,  
f) AEs,  
g) SAEs  
h) Efficacy.  
 
9 CLINICAL MONITORING  
This study may be participant to audit or inspection by [CONTACT_676898] [CONTACT_1744],  
DSMB or FDA.  
Data from this study will be monitored by [CONTACT_676899] , Clinilabs, for compliance with 
GCP principals.  Monitoring will include review of CRFs and other study documents for 
protocol compliance, data accuracy and completeness. Monitoring will include r eview of the 
investigator’s site file and drug handling records. Clinilabs  will be given direct access to 
source documents, CRFs and other study -related documents. By [CONTACT_617047], the participant authorize s Clinilabs  staff direct acce ss to their medical records and the 
study data.  
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915650] at the interim stage ( See 10.4.7 ), 
and second after the conclusion of all study procedures and database lock.  
 
10.2 STATISTICAL HYPOTHESES  
N/A 
 
10.[ADDRESS_915651]  75% of applicable time points.  
 
10.[ADDRESS_915652] 75% valid pharmacokinetic blood samples including 2 
consecutive monthly naltrexone blood levels recorded at <0.1  ng/mL will be analyzed.  
 
10.4.3  Analysis of t he Secondary  and Exploratory  Endpoint(s)  
Pharmacokinetic parameters (C max, Tmax and AUC 0-∞, the period of time from insertion that 
naltrexone plasma concentrations remain above 1.33 ng/m L) will be calculated using a non -
compartmental approach. Naltrexone plasma profiles will be plotted graphically for each 
individual and the study group (concentration -versus -time profile).  
Use of opi[INVESTIGATOR_2438], cocaine, marijuana, and alcohol for each day of the study will be determined 
based on results of urine toxic ology and self -report.  Proportion of days with substance use for 
each participant will be summarized.  
 
10.4.4  Safety Analyses  
The frequency of AEs including wound site and inflammatory response rates will be 
recorded. Any SAEs , adverse drug reactions, and suspec ted unexpected serious AE will be 
collated for the combined group. Additionally, counts of the number of laboratory values that 
fall outside of the normal range will be used to assess safety.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 63 of 78 10.4.5  Adherence and Retention Analyses  
The percentage of participants  that complete the desired number of follow up blood 
collection points will be calculated and presented with 95% confidence intervals.   
 
10.4.[ADDRESS_915653] deviation, median, 
interquartile range, percentages and 95% confidence intervals (where appropriate).  
 
10.4.7  Planned Interim Analyses  
[IP_ADDRESS]  Safety Review  
As per AE reporting, AEs will be collated and reviewed quarterly by [CONTACT_488930]. 
This may include crude rates of type specific AEs; however , no formal interim analysis will 
be conducted .  
 
[IP_ADDRESS]  Efficacy Review  
An interim analysis will be carried out once  at least [ADDRESS_915654] 14 of 19 vali d blood 
samples (including the Day 180 sample ) and safety data  will be evaluated whether or not they 
met the MEC criteria (naltrexone blood level above 1.33  ng/m L). The analyzed interim data 
will be used in the planning and design of a bioequivalence/safety study of the OLANI 
against a reference extended release nalt rexone product.  
 
10.4.8  Additional Sub -Group Analyses  
No sub -group analysis will be performed.  
 
10.4.9  Multiple Comparison/ Multiplicity  
No adjustment will be made for multiple comparisons.  
 
10.4.10 Tabulation of Individual Response Data  
Individual pharmacokinetic and safety  data will be tabulated for each time point and included 
in the appendices of the final study report.   
 
10.4.11 Exploratory Analyses  
No exploratory analysis will be conducted.  
 
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 64 of 78 10.5 SAMPLE SIZE  
At the completion of the study it is desirable that a minimum of 10 parti cipants complete a 
minimum of 75% blood collection time points , including 2 consecutive undetectable values  
(defined as naltrexone blood levels of <0.1  ng/mL ). 
 
10.6 MEASURES TO MINIMIZE BIAS  
10.6.1  Enrolment/ Randomization/ Masking Procedures  
N/A as there is no blinding  
 
10.6.2  Evaluation of Success of Blinding  
N/A as there is no blinding  
 
10.6.3  Breaking the Study Blind/Participant Code  
N/A as there is no blinding  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
Direct access to source data/documents will be provided to the sponsor, trial -related 
monitoring, audits, NYSPI [CONTACT_1744], and regulatory inspection(s).  
 
12 QUALITY ASSURANCE AND QUALITY CONTROL  
QC procedures will be implemented beginning with the data entry system  and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies 
will be communicated to the site(s) for clarification/resolution.  
Following written SOPs, the monitors will verify that the clinical trial is conduct ed and data 
are generated, documented (recorded) and reported in compliance with the protocol, GCP and 
the applicable regulatory requirements (e.g. Good Laboratory Practices (GLP), Good 
Manufacturing Practices (GMP).  
The investigational site will provide d irect access to all trial related sites, source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_1034] , CRO  
(Clinilabs)  and inspection by [CONTACT_3482].  
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 65 of 78 13 ETHICS/PROTECTION OF HUMAN PARTICIPANTS  
13.[ADDRESS_915655]  
The investigator will obta in NYSPI [INVESTIGATOR_676863]. Initial IRB approval as well 
as all materials approved by [CONTACT_7212], including the participant  consent form and 
recruitment materials.  
Annual Reports describing the study progress an d all AEs will be provided to the NYSPI 
[CONTACT_1744], along with a final study report by [CONTACT_978]. A copy of this report will also be provided to 
the sponsor.  
 
13.3 INFORMED CONSENT PROCESS  
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  
All stu dy participants will be provided with a  Participant Information Sheet (PIS) describing 
the study and providing sufficient information so that they are able to make an informed 
decision about their participation in the trial. Both the PIS and the Participant Informed 
Consent (PIC) form will be submitted with the research application for review and approval 
by [CONTACT_1201].  
 
13.3.2  Consent Procedures and Documentation  
The investigator (or authorized designee ) will  ensure that the participant  (or the participant ’s 
legal representative) is given full and adequate oral and written information about the nature, 
purpose, potential and possible risks and benefits of the study. Each prospective participant  
will receive an IRB -approved ICF that summarizes the  pertinent study information and will 
be given ample time to read the form and ask questions about the study. All information is to 
be provided in a language understandable to the participant  and must not include any 
language that waives the participant ’s legal rights. Prospective participant s must also be 
informed of their right to withdraw consent without prejudice at any time during the study. If 
the participant  chooses to participate, he/she must sign the ICF before any study -specific 
procedures are con ducted.  
 
13.[ADDRESS_915656] signed a confidentiality agreement 
with the PI [INVESTIGATOR_676864].  
All participant data will be de -identified by [CONTACT_676900].  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915657] protected 
and also limited to authorized  study personnel.  
Additionally,  a Federal Certificate of Confidentiality will be obtained.  
 
13.4.1  Research Use of Stored Human Samples, Specimens or Data  
[IP_ADDRESS]  Naltrex one blood  level  
Samples collected up to and including the 48 hour  time point will be prepared by [CONTACT_676901] [INVESTIGATOR_676865] -70ºC before shipment in batches to  the PK analysis 
laboratory . Samples collected after the 48 hour time  point will b e processed by [CONTACT_676902].  All 
samples will be analyzed  for free (unconjugated) naltrexone and free (unconjugated) 6 -β-
naltrexol quantification. It is anticipated that samples will prepared and split into 2 aliquots, 
with 1 being used for analysis and 1 serving as a backup being stored de -identified in a -70°C 
freezer. Samples will be kept for [ADDRESS_915658] 
protocols.  
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915659] KEEPI[INVESTIGATOR_1645]  
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
An electronic  Case Report Form ( eCRF) will be designed to record data required by [CONTACT_676903]. A n eCRF will be completed for each participa nt.  
A confidential list of participant names, contact [CONTACT_8972] , and screening numbers will be kept 
by [CONTACT_676904] . eCRF data removed from the study site will be 
identified by [CONTACT_676905] s or contact [CONTACT_8972].  
Data collection is the responsibility of the clinical trial staff at the site under the supervision 
of the site PI. The investigator is responsible for ensuring the accuracy, completeness, 
legibility and timeliness of the data reporte d. All source documents should be completed in a 
neat, legible manner to ensure accurate interpretation of data.  
 
14.2 STUDY RECORDS RETENTION   
Retention and storage of essential clinical study documents ( e.g. worksheets, drug 
accountability forms, and other administrative documentation) shall be governed by [CONTACT_676906].  
• Ten years after discontinuation of the study, or  
• Two years following the date a marketing application is approved for t he study drug for 
the indication for which it is being investigated pursuant to the study, or  
• If no application is to be filed or if the application is not approved for such indication, 
until 2 years after the date the study is terminated.  
Participant s’ medical files should be retained in accordance with the applicable legislation 
and in accordance with the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], institution, or 
private practice  
 
14.3 PROTOCOL DEVIATIONS   
A protocol deviation is any noncompliance with  the clinical trial protocol, SOP’s and GCP 
requirements. The noncompliance may be either on the part of the participant, the 
investigator, or the study site staff  at the SURC clinic, CUMC, or Clinilabs clinic . As a result 
of deviations, corrective actions  are to be developed by [CONTACT_3483].  
The PI [INVESTIGATOR_676866], or changes of the protocol without 
agreement by [CONTACT_335958]/ favorable  opi[INVESTIGATOR_676867], except where n ecessary to eliminate an immediate hazard(s) to trial participants, 
or when the change(s) involves only logistical or administrative aspects of the trial (e.g., 
change in monitor(s), change of telephone number(s)).  
If the PI [INVESTIGATOR_676868] a deviation from, or  a change of, the protocol to eliminate an immediate 
hazard(s) to trial participants, without prior approval/ favorable  opi[INVESTIGATOR_676869] . As 
soon as possible, the implemented deviation or change, the reasons for it, and, if appropriate, 
the proposed p rotocol amendment(s) should be submitted:  
• To NYSPI [INVESTIGATOR_676870]/ favorable  opi[INVESTIGATOR_1649],  
• To the sponsor for agreement and, if required,  
• To the regulatory authority.  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page [ADDRESS_915660] udy personnel from 
NYS  Psychiatric Institute . A Clinical Study Report will be issued which may form the b asis 
of a manuscript intended for publication. Any publications arising from this study will be 
published by a process of peer review.  
 
15 STUDY ADMINISTRATION  
15.1 STUDY LEADERSHIP  
The study leadership will be composed of the PI, the Responsible Clinician, Sponsor 
Representative , and site representative  (See section 1) 
 
[ADDRESS_915661].  
 
  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 77 of 78 19 LITERATURE REFERENCES  
1. Wall, M. E., Brine, D. R. & Perez -Reyes, M. The metabolism of naltrexone in man. 
NIDA Res. Monogr.  28, 105–31 (1981).  
2. Alkermes. FDA Psychopharmacologic Drugs Advisory Committee Meeting Vivitrol® 
(naltrexone for extended -release injectable suspension) ND A 21 -897. 165 (2010).  
3. Wall, M. E., Perez -Reyes, M., Brine, D. R. & Cook, C. E. Naltrexone disposition in 
man after subcutaneous administration. Drug Metab. Dispos.  12, 677–82 (1984).  
4. Rukstalis, M. R., Stromberg, M. F., O’Brien, C. P. & Volpi[INVESTIGATOR_48536], J.  R. 6-beta-naltrexol 
reduces alcohol consumption in rats. Alcohol. Clin. Exp. Res.  24, 1593 –6 (2000).  
5. McCaul, M. E., Wand, G. S., Rohde, C. & Lee, S. M. Serum 6 -beta-naltrexol levels are 
related to alcohol responses in heavy drinkers. Alcohol. Clin. Exp . Res.  24, 1385 –91 
(2000).  
6. Meyer, M. C., Straughn, A. B., Lo, M. W., Schary, W. L. & Whitney, C. C. 
Bioequivalence, dose -proportionality, and pharmacokinetics of naltrexone after oral 
administration. J. Clin. Psychiatry  45, 15–9 (1984).  
7. Porter, S. J. , Somogyi, A. A. & White, J. M. Kinetics and inhibition of the formation of 
6beta -naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol.  50, 
465–71 (2000).  
8. Bell, J. R. et al.  A pi[INVESTIGATOR_676871] -accelerated detoxification in o pi[INVESTIGATOR_2560]. Med. J. Aust.  171, 26–30 (1999).  
9. Duramed Pharmaceuticals. REVIA®, US Package Insert. Reference ID: 3383348 
(2013).  
10. Hulse, G. K. & Basso, M. R. The association between naltrexone compliance and daily 
supervision. Drug Alcohol Rev.  19, 41–48 (2000).  
11. Gevirtz, C. Rapid Opi[INVESTIGATOR_224525]. JAMA  279, 1871 (1998).  
12. Brewer, C. Naltrexone implants for opi[INVESTIGATOR_15825]: New life for a middle -aged drug. 
Pharm. J.  267, 260 (2001).  
13. Brewer, C. Naltrexone: An ‘Antiabuse’ for heroin addicts? Pharm. J.  239, 182–183 
(1987).  
14. Wise, D. L. in Biopolymeric Controlled Release Systems  (ed. Wise, D. L.) 115 –181 
(CRC Press, 1984).  
15. Yamaguchi, K. & Anderson, J. M. In vivo biocompatibility st udies of medisorb® 
65/35 D,L -lactide/glycolide copolymer microspheres. J. Control. Release  24, 81–93 
(1993).  
16. Schwope, A. D., Wise, D. L. & Howes, J. F. Lactic/glycolic acid polymers as narcotic 
antagonist delivery systems. Life Sci.  17, 1877 –1885 (1975 ). 
17. Yolles, S., Leafe, T. D., Woodland, J. H. R. & Meyer, F. J. Long acting delivery 
systems for narcotic antagonists II: Release rates of naltrexone from poly(lactic acid) 
composites. J. Pharm. Sci.  64, 348–349 (1975).  
18. Chiang, C. N., Hollister, L. E., Kishimoto,  a & Barnett, G. Kinetics of a naltrexone 
sustained -release preparation. Clin. Pharmacol. Ther.  36, 704–8 (1984).  
A PI[INVESTIGATOR_676815] O’NEIL LONG ACTING NALTREXONE IMPLANT  
CONFIDENTIAL      Go-Medical Protocol GM0017 : (Ver. 0.13; 11 June 2020)    
 
Page 78 of 78 19. Maa, Y. F. & Heller, J. Controlled release of naltrexone pamoate from linear 
poly(ortho esters). J. Control. Release  14, 21–28 (1990).  
20. Pettinati, H. M., Gastfriend, D. R., Dong, Q., Kranzler, H. R. & O’Malley, S. S. Effect 
of Extended -Release Naltrexone (XR -NTX) on Quality of Life in Alcohol -Dependent 
Patients. Alcohol. Clin. Exp. Res.  33, 350–356 (2009).  
21. Krupi[INVESTIGATOR_25195], E.  Injectable extended -release naltrexone for the prevention of relapse to 
opi[INVESTIGATOR_676872]. Neuropsychiatry (London).  2, 355–
362 (2012).  
22. Johnson, B. A. et al.  A pi[INVESTIGATOR_676873] d ose 
administration of long -acting injectable naltrexone (Vivitrex) in patients with alcohol 
dependence. Alcohol. Clin. Exp. Res.  28, 1356 –61 (2004).  
23. Kunøe, N., Lobmaier, P., Ngo, H. & Hulse, G. Injectable and implantable sustained 
release naltrexone in  the treatment of opi[INVESTIGATOR_9827]. Br. J. Clin. Pharmacol.  77, 
264–71 (2014).  
24. Beck, L. R. et al.  Clinical evaluation of injectable biodegradable contraceptive system. 
Am. J. Obstet. Gynecol.  140, 799–806 (1981).  
25. Perrin, D. E. & English, J. P. in Handbook of Biodegradable Polymers  (eds. Domb, A. 
J., Kost, J. & Wiseman, D. M.) 3 –27 (Taylor & Francis, 1997).  
26. Brahen, L. S., Capone, T. J. & Capone, D. M. Naltrexone: Lack of Effect on Hepatic 
Enzymes. J. Clin. Pharm acol.  28, 64–70 (1988).  
27. Brewer, C. & Wong, V. S. Naltrexone: report of lack of hepatotoxicity in acute viral 
hepatitis, with a review of the literature. Addict. Biol.  9, 81–7 (2004).  
28. Lucey, M. R., Silverman, B. L., Illeperuma, A. & O’Brien, C. P. H epatic safety of 
once -monthly injectable extended -release naltrexone administered to actively drinking 
alcoholics. Alcohol. Clin. Exp. Res.  32, 498–504 (2008).  
29. Mitchell, M. C., Memisoglu, A. & Silverman, B. L. Hepatic Safety of Injectable 
Extended -Release Naltrexone in Patients With Chronic Hepatitis C and HIV Infection. 
J. Stud. Alcohol Drugs  73, 991–997 (2012).  
30. Tetrault, J. M. et al.  Hepatic safety and antiretroviral effectiveness in HIV -infected 
patients receiving naltrexone. Alcohol. Clin. Exp. Res. 36, 318–24 (2012).  
31. Vagenas, P. et al.  Corrigendum to ‘An evaluation of hepatic enzyme elevations among 
HIV-infected released prisoners enrolled in two randomized placebo -controlled trials 
of extended release naltrexone’ [Journal of Substance Abuse  Treatment 47 (2014) 35 –
40](S0740547214000415). J. Subst. Abuse Treat.  77, 44 (2017).  
32. Therapeutic Goods Administration. NOTE FOR GUIDANCE ON GOOD CLINICAL 
PRACTICE (CPMP/ICH/135/95) . Department of Health And Aged Care  (TGA 
Publications Office, 2000).  
33. World Health Organisation. World Medical Association Declaration of Helsinki. 
JAMA  310, 2191 (2013).  
 